BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030. [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] [Cited by in Crossref: 657] [Cited by in F6Publishing: 628] [Article Influence: 65.7] [Reference Citation Analysis]
Number Citing Articles
1 Pulvirenti G, Sortino V, Manti S, Parisi GF, Papale M, Giallongo A, Leonardi S. Pathogenesis, diagnosis, dietary management, and prevention of gastrointestinal disorders in the paediatric population. Ital J Pediatr 2022;48. [DOI: 10.1186/s13052-022-01366-8] [Reference Citation Analysis]
2 Nishida M, Hasegawa Y, Hata J. Basic practices for gastrointestinal ultrasound. J Med Ultrason (2001) 2022. [PMID: 36087155 DOI: 10.1007/s10396-022-01236-0] [Reference Citation Analysis]
3 Agraib LM, Yamani MI, Tayyem R, Abu-sneineh AT, Rayyan YM. Probiotic supplementation induces remission and changes in the immunoglobulins and inflammatory response in active ulcerative colitis patients: A pilot, randomized, double-blind, placebo-controlled study. Clinical Nutrition ESPEN 2022. [DOI: 10.1016/j.clnesp.2022.08.020] [Reference Citation Analysis]
4 Lopes MB, Lyra AC, Rocha R, Coqueiro FG, Lima CA, de Oliveira CC, Santana GO. Overweight and abdominal fat are associated with normal bone mineral density in patients with ulcerative colitis. World J Gastrointest Pharmacol Ther 2022; 13(4): 57-66 [DOI: 10.4292/wjgpt.v13.i4.57] [Reference Citation Analysis]
5 Elhag DA, Kumar M, Saadaoui M, Akobeng AK, Al-mudahka F, Elawad M, Al Khodor S. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. IJMS 2022;23:6966. [DOI: 10.3390/ijms23136966] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Macleod A, Kavalukas SL, Scheurlen KM, Galandiuk S. State-of-the-art surgery for Crohn's disease: Part II-colonic Crohn's disease and associated neoplasms. Langenbecks Arch Surg 2022. [PMID: 35729401 DOI: 10.1007/s00423-022-02572-y] [Reference Citation Analysis]
7 Hu W, Fang T, Chen X. Identification of Differentially Expressed Genes and miRNAs for Ulcerative Colitis Using Bioinformatics Analysis. Front Genet 2022;13:914384. [DOI: 10.3389/fgene.2022.914384] [Reference Citation Analysis]
8 Salama RM, Darwish SF, El Shaffei I, Elmongy NF, Fahmy NM, Afifi MS, Abdel-Latif GA. Morus macroura Miq. Fruit extract protects against acetic acid-induced ulcerative colitis in rats: Novel mechanistic insights on its impact on miRNA-223 and on the TNFα/NFκB/NLRP3 inflammatory axis. Food Chem Toxicol 2022;:113146. [PMID: 35595039 DOI: 10.1016/j.fct.2022.113146] [Reference Citation Analysis]
9 Selimagic A, Dozic A, Husic-selimovic A, Tucakovic N, Cehajic A, Subo A, Spahic A, Vanis N. The Role of Inflammation in Anal Cancer. Diseases 2022;10:27. [DOI: 10.3390/diseases10020027] [Reference Citation Analysis]
10 Xu F, Tang J, Zhu Z, Chen Y, Hu W, Lu S, Zhou Y, Lin D. Medication Adherence and Its Influencing Factors Among Inflammatory Bowel Disease Patients in China. IJGM 2022;Volume 15:4141-9. [DOI: 10.2147/ijgm.s359082] [Reference Citation Analysis]
11 Thomsen SB, Ungaro RC, Allin KH, Elmahdi R, Poulsen G, Andersson M, Colombel JF, Jess T. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study. Aliment Pharmacol Ther 2022. [PMID: 35080036 DOI: 10.1111/apt.16777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Peyrin-biroulet L, Siegmund B, Danese S, Hart A, Magro F, van der Woude J, Armuzzi A; ECCO Governing Board. Letter to the Editor. Journal of Crohn's and Colitis 2022. [DOI: 10.1093/ecco-jcc/jjab225] [Reference Citation Analysis]
13 Raman M, Ma C, Taylor LM, Dieleman LA, Gkoutos GV, Vallance JK, McCoy KD, Lewis I, Jijon H, McKay DM, Mutch DM, Barkema HW, Gibson D, Rauch M, Ghosh S. Crohn's disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial. BMJ Open Gastroenterol 2022;9:e000841. [PMID: 35046093 DOI: 10.1136/bmjgast-2021-000841] [Reference Citation Analysis]
14 Caravaca AS, Levine YA, Drake A, Eberhardson M, Olofsson PS. Vagus Nerve Stimulation Reduces Indomethacin-Induced Small Bowel Inflammation. Front Neurosci 2022;15:730407. [DOI: 10.3389/fnins.2021.730407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Takahara M, Hiraoka S, Ohmori M, Takeuchi K, Takei K, Yasutomi E, Igawa S, Yamamoto S, Yamasaki Y, Inokuchi T, Kinugasa H, Harada K, Ohnishi H, Okada H. The Colon Wall Thickness Measured Using Transabdominal Ultrasonography is Useful for Detecting Mucosal Inflammation in Ulcerative Colitis. Intern Med . [DOI: 10.2169/internalmedicine.8827-21] [Reference Citation Analysis]
16 Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Pranzo G, Rodinò S, Scarcelli A, Zampaletta C, Brozzi L, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Fiorella S, Iannelli C, Larussa T, Le Grazie M, Luppino I, Meucci C, FaggianI R, Pagnini C, Perazzo P, Rodriguez-Castro KI, Sacco R, Sebkova L, Serio M, De Monti A, Picchio M, Napolitano D, Schiavoni E, Turchini L, Scaldaferri F, Pugliese D, Guidi L, Laterza L, Privitera G, Pizzoferrato M, Lopetuso LR, Armuzzi A, Elisei W, Maconi G, Papa A. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. Expert Opin Biol Ther 2021;:1-8. [PMID: 34904510 DOI: 10.1080/14712598.2022.2007881] [Reference Citation Analysis]
17 Nejati S, Wang J, Heredia-Rivera U, Sedaghat S, Woodhouse I, Johnson JS, Verma M, Rahimi R. Small intestinal sampling capsule for inflammatory bowel disease type detection and management. Lab Chip 2021;22:57-70. [PMID: 34826326 DOI: 10.1039/d1lc00451d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Chen Y, Niu Y, Hao W, Zhang W, Lu J, Zhou J, Du L, Xie W. Pineapple Leaf Phenols Attenuate DSS-Induced Colitis in Mice and Inhibit Inflammatory Damage by Targeting the NF-κB Pathway. Molecules 2021;26:7656. [PMID: 34946738 DOI: 10.3390/molecules26247656] [Reference Citation Analysis]
19 Zhang J, Wang W, Zhu S, Chen Y. Increased SERPINA3 Level Is Associated with Ulcerative Colitis. Diagnostics (Basel) 2021;11:2371. [PMID: 34943607 DOI: 10.3390/diagnostics11122371] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Guillo L, Delanaye P, Flamant M, Figueres L, Karam S, Lemoine S, Benezech A, Pelletier AL, Amiot A, Caron B, Stefanescu C, Boschetti G, Bouguen G, Rahier JF, Gornet JM, Hugot JP, Bonnet J, Vuitton L, Nachury M, Vidon M, Uzzan M, Serrero M, Dib N, Seksik P, Hebuterne X, Bertocchio JP, Mariat C, Peyrin-Biroulet L. Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Dig Liver Dis 2021:S1590-8658(21)00848-3. [PMID: 34866011 DOI: 10.1016/j.dld.2021.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Kim G, Jang M, Hwang I, Cho J, Kim S. Radish sprout alleviates DSS-induced colitis via regulation of NF-kB signaling pathway and modifying gut microbiota. Biomed Pharmacother 2021;144:112365. [PMID: 34794235 DOI: 10.1016/j.biopha.2021.112365] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
22 Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Peyrin-Biroulet L, Colombel JF, Kaplan GG, Chen MH. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology 2021:S0016-5085(21)03709-4. [PMID: 34757139 DOI: 10.1053/j.gastro.2021.10.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
23 Bhandari R, Ogeyingbo OD, Kareem R, Gyawali M, Venkatesan N, Ahmed R, Botleroo RA, Elshaikh AO. Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review. Cureus 2021;13:e17729. [PMID: 34659943 DOI: 10.7759/cureus.17729] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Bekkers M, Stojkovic B, Kaiko GE. Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease. Int J Mol Sci 2021;22:11243. [PMID: 34681902 DOI: 10.3390/ijms222011243] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
25 Zhang L, Wu YB, Dai YK, Liu Q, Ren YJ, Xu SJ, Pan HG, Chen WJ, Li RL, Hu L. Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis. PLoS One 2021;16:e0257599. [PMID: 34543327 DOI: 10.1371/journal.pone.0257599] [Reference Citation Analysis]
26 Weislinger L, Guillo L, D'Amico F, Danese S, Achit H, Ayav C, Guillemin F, Peyrin-Biroulet L, Frimat L. Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2021;33:1148-52. [PMID: 33252416 DOI: 10.1097/MEG.0000000000002008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Agraib LM, Yamani MI, Rayyan YM, Abu-Sneineh AT, Tamimi TA, Tayyem RF. The probiotic supplementation role in improving the immune system among people with ulcerative colitis: a narrative review. Drug Metab Pers Ther 2021;37:7-19. [PMID: 35385892 DOI: 10.1515/dmpt-2021-0150] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Agraib LM, Yamani MI, Rayyan YM, Abu-Sneineh AT, Tamimi TA, Tayyem RF. The probiotic supplementation role in improving the immune system among people with ulcerative colitis: a narrative review. Drug Metab Pers Ther 2021. [PMID: 34428363 DOI: 10.1515/dmdi-2021-0150] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Tursi A, Mocci G, Lorenzetti R, Allegretta L, Brandimarte G, Cassieri C, Colucci R, De Medici A, Faggiani R, Ferronato A, Fiorella S, Forti G, Franceschi M, Gallina S, Giorgetti G, Grasso G, Larussa T, Luzza F, Penna A, Pica R, Piergallini S, Porciello S, Pranzo G, Rodino' S, Scorza S, Sebkova L, Zampaletta C, Elisei W, Picchio M. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur J Gastroenterol Hepatol 2021;33:670-9. [PMID: 33741797 DOI: 10.1097/MEG.0000000000002087] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
30 Chapman S, Sibelli A, St-Clair Jones A, Forbes A, Chater A, Horne R. Personalised Adherence Support for Maintenance Treatment of Inflammatory Bowel Disease: A Tailored Digital Intervention to Change Adherence-related Beliefs and Barriers. J Crohns Colitis 2020;14:1394-404. [PMID: 32379303 DOI: 10.1093/ecco-jcc/jjz034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
31 Mortensen JH, van Haaften WT, Karsdal MA, Bay-Jensen AC, Olinga P, Grønbæk H, Hvas CL, Manon-Jensen T, Dijkstra G, Dige A. The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease. J Clin Gastroenterol 2021;55:59-66. [PMID: 32301833 DOI: 10.1097/MCG.0000000000001341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
32 Bertani L, Blandizzi C, Mumolo MG, Ceccarelli L, Albano E, Tapete G, Baiano Svizzero G, Zanzi F, Coppini F, de Bortoli N, Bellini M, Morganti R, Marchi S, Costa F. Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. Clin Transl Gastroenterol 2020;11:e00174. [PMID: 32677804 DOI: 10.14309/ctg.0000000000000174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
33 Shin J, Kong SM, Kim TJ, Kim ER, Hong SN, Chang DK, Kim YH. Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission. Gut Liver 2021;15:401-9. [PMID: 32839361 DOI: 10.5009/gnl20078] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Yu RG, Zhang JY, Liu ZT, Zhuo YG, Wang HY, Ye J, Liu N, Zhang YY. Text Mining-Based Drug Discovery in Osteoarthritis. J Healthc Eng 2021;2021:6674744. [PMID: 33953899 DOI: 10.1155/2021/6674744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 March-Luján VA, Prado-Gascó V, Huguet JM, Cortés X, Arquiola JMP, Capilla-Igual M, Josefa-Rodríguez-Morales M, Monzó-Gallego A, Armero JLP, Ortí JER. Impact of BMGIM Music Therapy on Emotional State in Patients with Inflammatory Bowel Disease: A Randomized Controlled Trial. J Clin Med 2021;10:1591. [PMID: 33918724 DOI: 10.3390/jcm10081591] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Teixeira FV, Hosne RS, Sobrado CW. Management of ulcerative colitis: a clinical update. Journal of Coloproctology 2021;35:230-7. [DOI: 10.1016/j.jcol.2015.08.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
38 Guillo L, D'Amico F, Achit H, Ayav C, Guillemin F, Danese S, Frimat L, Peyrin-Biroulet L. Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. Dig Liver Dis 2021;53:691-6. [PMID: 33563584 DOI: 10.1016/j.dld.2021.01.015] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
39 Gugliesi F, Pasquero S, Griffante G, Scutera S, Albano C, Pacheco SFC, Riva G, Dell'Oste V, Biolatti M. Human Cytomegalovirus and Autoimmune Diseases: Where Are We? Viruses 2021;13:260. [PMID: 33567734 DOI: 10.3390/v13020260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
40 Lan YZ, Bai YL, Zhu XD. Integrated Traditional Chinese and Western medicine for ulcerative colitis with diabetes: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24444. [PMID: 33530250 DOI: 10.1097/MD.0000000000024444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Jacob EM, Borah A, Pillai SC, Kumar DS. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials (Basel) 2020;10:E2460. [PMID: 33316984 DOI: 10.3390/nano10122460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
42 Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14:254-266. [PMID: 31403666 DOI: 10.1093/ecco-jcc/jjz131] [Cited by in Crossref: 50] [Cited by in F6Publishing: 77] [Article Influence: 25.0] [Reference Citation Analysis]
43 Tian Y, Cui L, Lin C, Wang Y, Liu Z, Miao X. LncRNA CDKN2B-AS1 relieved inflammation of ulcerative colitis via sponging miR-16 and miR-195. Int Immunopharmacol 2020;88:106970. [PMID: 33182065 DOI: 10.1016/j.intimp.2020.106970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
44 Martínez-Feito A, Bravo-Gallego LY, Hernández-Breijo B, Diez J, García-Ramirez L, Jaquotot M, Plasencia-Rodríguez C, Nozal P, Mezcua A, Martín-Arranz MD, Pascual-Salcedo D. Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. Sci Rep 2020;10:17099. [PMID: 33051546 DOI: 10.1038/s41598-020-74235-1] [Reference Citation Analysis]
45 Florholmen JR, Johnsen KM, Meyer R, Olsen T, Moe ØK, Tandberg P, Gundersen MD, Kvamme JM, Johnsen K, Løitegård T, Raschpichler G, Vold C, Sørbye SW, Goll R. Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis. BMC Gastroenterol 2020;20:321. [PMID: 33008302 DOI: 10.1186/s12876-020-01447-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
46 Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:689-704. [PMID: 33121689 DOI: 10.1016/j.gtc.2020.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Munakata K, Koi M, Kitajima T, Tseng-Rogenski S, Uemura M, Matsuno H, Kawai K, Sekido Y, Mizushima T, Toiyama Y, Yamada T, Mano M, Mita E, Kusunoki M, Mori M, Carethers JM. Inflammation-Associated Microsatellite Alterations Caused by MSH3 Dysfunction Are Prevalent in Ulcerative Colitis and Increase With Neoplastic Advancement. Clin Transl Gastroenterol 2019;10:e00105. [PMID: 31789935 DOI: 10.14309/ctg.0000000000000105] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
49 Matsuoka K, Igarashi A, Sato N, Isono Y, Gouda M, Iwasaki K, Shoji A, Hisamatsu T. Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016. J Crohns Colitis 2021;15:358-66. [PMID: 32845311 DOI: 10.1093/ecco-jcc/jjaa172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
50 Helmy AM, Elsabahy M, Abd-elkareem M, Ibrahim EA, Soliman GM. High-Payload chitosan microparticles for the colonic delivery of quercetin: Development and in-vivo evaluation in a rabbit colitis model. Journal of Drug Delivery Science and Technology 2020;58:101832. [DOI: 10.1016/j.jddst.2020.101832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
51 de Jong MJ, Boonen A, van der Meulen-de Jong AE, Romberg-camps MJ, van Bodegraven AA, Mahmmod N, Markus T, Dijkstra G, Winkens B, van Tubergen A, Masclee A, Jonkers DM, Pierik MJ. Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial. Clinical Gastroenterology and Hepatology 2020;18:1744-52. [DOI: 10.1016/j.cgh.2020.04.038] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
52 Bademci R, Erdoğan MA, Kara AY, Yiğittürk G, Erbaş O. Therapeutic effects of vitamin D on acetic acid-induced colitis in rats. Acta Cir Bras 2020;35:e202000404. [PMID: 32555936 DOI: 10.1590/s0102-865020200040000004] [Reference Citation Analysis]
53 Frontali A, Cohen L, Bridoux V, Myrelid P, Sica G, Poggioli G, Espin E, Beyer-Berjot L, Laharie D, Spinelli A, Zerbib P, Sampietro G, Frasson M, Louis E, Danese S, Fumery M, Denost Q, Altwegg R, Nancey S, Michelassi F, Treton X, Panis Y. Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients. J Crohns Colitis 2020:jjaa107. [PMID: 32498084 DOI: 10.1093/ecco-jcc/jjaa107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
54 Rondanelli M, Lamburghini S, Faliva MA, Peroni G, Riva A, Allegrini P, Spadaccini D, Gasparri C, Iannello G, Infantino V, Alalwan TA, Perna S, Miccono A. A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease. Endocrinol Diabetes Nutr (Engl Ed) 2021;68:17-46. [PMID: 32499202 DOI: 10.1016/j.endinu.2020.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
55 Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis 2018;12:1021-9. [PMID: 29767728 DOI: 10.1093/ecco-jcc/jjy049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
56 Takatsu N, Hisabe T, Higashi D, Ueki T, Matsui T. Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy. Core Evid 2020;15:7-20. [PMID: 32280316 DOI: 10.2147/CE.S179053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
57 Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR. The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. J Crohns Colitis 2019;13:1217-26. [PMID: 30879034 DOI: 10.1093/ecco-jcc/jjz038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
58 Carvello M, Watfah J, Włodarczyk M, Spinelli A. The Management of the Hospitalized Ulcerative Colitis Patient: the Medical-Surgical Conundrum. Curr Gastroenterol Rep 2020;22:11. [PMID: 32040642 DOI: 10.1007/s11894-020-0750-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Oliphant K, Cochrane K, Schroeter K, Daigneault MC, Yen S, Verdu EF, Allen-Vercoe E. Effects of Antibiotic Pretreatment of an Ulcerative Colitis-Derived Fecal Microbial Community on the Integration of Therapeutic Bacteria In Vitro. mSystems 2020;5:e00404-19. [PMID: 31992630 DOI: 10.1128/mSystems.00404-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
60 Angelison L, Almer S, Davidsdottir L, Hammarlund P, Lindgren S, Hindorf U, Marsal J, Hertervig E. Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study. Scand J Gastroenterol 2020;55:154-62. [PMID: 31961234 DOI: 10.1080/00365521.2020.1713210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Bischoff SC, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, Forbes A. ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. Clin Nutr 2020;39:632-53. [PMID: 32029281 DOI: 10.1016/j.clnu.2019.11.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 84] [Article Influence: 22.0] [Reference Citation Analysis]
62 Bar-Yoseph H, Daoud H, Ben Hur D, Chowers Y, Waterman M. Does early corticosteroid therapy affect prognosis in IBD patients hospitalized with Clostridioides difficile infection? Int J Colorectal Dis 2020;35:513-9. [PMID: 31927638 DOI: 10.1007/s00384-019-03502-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
63 Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357-1373. [PMID: 31272578 DOI: 10.1016/j.mayocp.2019.01.018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 101] [Article Influence: 27.0] [Reference Citation Analysis]
64 Kim DH, Kim S, Ahn JB, Kim JH, Ma HW, Seo DH, Che X, Park KC, Jeon JY, Kim SY, Lee HC, Lee JY, Kim TI, Kim WH, Kim SW, Cheon JH. Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice. Int J Med Microbiol. 2020;310:151391. [PMID: 32007342 DOI: 10.1016/j.ijmm.2020.151391] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
65 Simian D, Flores L, Quera R, Ibáñez P, Figueroa C, Lubascher J, Pizarro G, Kronberg U. The Role of an Inflammatory Bowel Disease Nurse in the Follow-Up of Patients From a Latin American Inflammatory Bowel Disease Program: . Gastroenterology Nursing 2020;43:E16-23. [DOI: 10.1097/sga.0000000000000436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
66 Shibuya T, Nomura K, Okahara K, Haga K, Nomura O, Murakami T, Uchida S, Kodani T, Ishikawa D, Sakamoto N, Ogihara T, Osada T, Nagahara A. Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy. Med Sci Monit 2019;25:9855-63. [PMID: 31865359 DOI: 10.12659/MSM.918562] [Reference Citation Analysis]
67 Picchianti-Diamanti A, Lorenzetti R, Chimenti MS, Luchetti MM, Conigliaro P, Canofari C, Benfaremo D, Bruzzese V, Laganà B, Perricone R; SIGR. Enteropathic spondyloarthritis: Results from a large nationwide database analysis. Autoimmun Rev 2020;19:102457. [PMID: 31838160 DOI: 10.1016/j.autrev.2019.102457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
68 Beyer-Berjot L, Baumstarck K, Loubière S, Vicaut E, Berdah SV, Benoist S, Lefèvre JH; GETAID Chirurgie group. Is diverting loop ileostomy necessary for completion proctectomy with ileal pouch-anal anastomosis? A multicenter randomized trial of the GETAID Chirurgie group (IDEAL trial): rationale and design (NCT03872271). BMC Surg 2019;19:192. [PMID: 31830976 DOI: 10.1186/s12893-019-0657-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
69 Cross RK, Chiorean M, Vekeman F, Xiao Y, Wu E, Chao J, Wang AW. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLoS One 2019;14:e0225572. [PMID: 31800627 DOI: 10.1371/journal.pone.0225572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
70 Baehler C, Brüngger B, Blozik E, Vavricka SR, Schoepfer AM. Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis. Inflamm Intest Dis 2019;4:144-53. [PMID: 31768387 DOI: 10.1159/000502205] [Reference Citation Analysis]
71 Lightner AL, Regueiro M, Click B. Special Considerations for Colorectal Surgery in the Elderly IBD Patient. Curr Treat Options Gastroenterol 2019;17:449-56. [PMID: 31755072 DOI: 10.1007/s11938-019-00254-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
72 Zhu J, Wang Z, Chen F, Liu C. Identification of genes and functional coexpression modules closely related to ulcerative colitis by gene datasets analysis. PeerJ 2019;7:e8061. [PMID: 31741804 DOI: 10.7717/peerj.8061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
73 Sokollik C, Fournier N, Rizzuti D, Braegger CP, Nydegger A, Schibli S, Spalinger J; Swiss IBD Cohort Study Group. The Use of 5-Aminosalicylic Acid in Children and Adolescents With Inflammatory Bowel Disease. J Clin Gastroenterol 2018;52:e87-91. [PMID: 28644308 DOI: 10.1097/MCG.0000000000000864] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
74 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos KH, Croft N, Navas-López VM, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. [PMID: 30044358 DOI: 10.1097/MPG.0000000000002036] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 21.3] [Reference Citation Analysis]
75 GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17-30. [PMID: 31648971 DOI: 10.1016/s2468-1253(19)30333-4] [Cited by in Crossref: 514] [Cited by in F6Publishing: 461] [Article Influence: 171.3] [Reference Citation Analysis]
76 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
77 Selinger CP, Parkes GC, Bassi A, Limdi JK, Ludlow H, Patel P, Smith M, Saluke S, Ndlovu Z, George B, Saunders J, Adamson M, Fraser A, Robinson J, Donovan F, Parisi I, Tidbury J, Gray L, Pollok R, Scott G, Raine T. Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients. Aliment Pharmacol Ther. 2019;50:1009-1018. [PMID: 31595533 DOI: 10.1111/apt.15497] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
78 Al-Omar HA, Sherif HM, Mayet AY. Vaccination status of patients using anti-TNF therapy and the physicians' behavior shaping the phenomenon: Mixed-methods approach. PLoS One 2019;14:e0223594. [PMID: 31584996 DOI: 10.1371/journal.pone.0223594] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
79 Ogrič M, Žigon P, Drobne D, Štabuc B, Sodin-Semrl S, Čučnik S, Praprotnik S. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels. Immunol Res 2018;66:726-36. [PMID: 30569379 DOI: 10.1007/s12026-018-9050-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
80 Valizadeh A, Sanaei R, Rezaei N, Azizi G, Fekrvand S, Aghamohammadi A, Yazdani R. Potential role of regulatory B cells in immunological diseases. Immunol Lett 2019;215:48-59. [PMID: 31442542 DOI: 10.1016/j.imlet.2019.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
81 Rodríguez-Lago I, Merino O, López de Goicoechea MJ, Aranzamendi M, Zubiaurre L, Muro N, Ortiz de Zárate J, Cilla G, Cabriada JL. Immunosuppression for inflammatory bowel disease does not influence Epstein-Barr viral load in the short-term. Gastroenterol Hepatol 2019;42:542-7. [PMID: 31402179 DOI: 10.1016/j.gastrohep.2019.03.016] [Reference Citation Analysis]
82 Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, Che T, Zhang C. Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens 2019;8:E126. [PMID: 31412603 DOI: 10.3390/pathogens8030126] [Cited by in Crossref: 127] [Cited by in F6Publishing: 201] [Article Influence: 42.3] [Reference Citation Analysis]
83 Fofaria RK, Barber S, Adeleke Y, Woodcock T, Kamperidis N, Mohamed A, Misra R, Shah A, Bailey-Fee S, Bluston H, Robinson D, Tyrrell T, Arebi N. Stratification of inflammatory bowel disease outpatients by disease activity and risk of complications to guide out-of-hospital monitoring: a patient-centred quality improvement project. BMJ Open Qual. 2019;8:e000546. [PMID: 31428704 DOI: 10.1136/bmjoq-2018-000546] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Burke KE, Khalili H, Garber JJ, Haritunians T, McGovern DPB, Xavier RJ, Ananthakrishnan AN. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. Inflamm Bowel Dis 2018;24:1840-8. [PMID: 29718226 DOI: 10.1093/ibd/izy083] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
85 Jairath V, Hokkanen SRK, Guizzetti L, Boxall N, Campbell-hill S, Patel H. No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study. Aliment Pharmacol Ther 2019;50:416-24. [DOI: 10.1111/apt.15408] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
86 Weder B, Mozaffari M, Biedermann L, Mamie C, Moncsek A, Wang L, Clarke SH, Rogler G, McRae BL, Graff CL, Ruiz PA, Hausmann M. BCL-2 levels do not predict azathioprine treatment response in inflammatory bowel disease, but inhibition induces lymphocyte apoptosis and ameliorates colitis in mice. Clin Exp Immunol 2018;193:346-60. [PMID: 29745420 DOI: 10.1111/cei.13151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
87 Lissel M, Omidy S, Myrelid P, Block M, Angenete E. The Handling of the Rectal Stump Does Not Affect Severe Morbidity After Subtotal Colectomy For Ulcerative Colitis: A Retrospective Cohort Study. Scand J Surg 2020;109:238-43. [DOI: 10.1177/1457496919857269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Medici A, Forti G, Franceschi M, Ferronato A, Gallina S, Grasso G, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino' S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Scorza S, Zampaletta C, Picchio M, Elisei W. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers. Eur J Intern Med 2019;66:85-91. [PMID: 31208827 DOI: 10.1016/j.ejim.2019.06.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
89 Kirov S, Sasson A, Zhang C, Chasalow S, Dongre A, Steen H, Stensballe A, Andersen V, Birkelund S, Bennike TB. Degradation of the extracellular matrix is part of the pathology of ulcerative colitis. Mol Omics 2019;15:67-76. [PMID: 30702115 DOI: 10.1039/c8mo00239h] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
90 Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World J Gastroenterol 2019; 25(18): 2162-2176 [PMID: 31143068 DOI: 10.3748/wjg.v25.i18.2162] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 51] [Article Influence: 21.7] [Reference Citation Analysis]
91 Bon L, Scharl S, Vavricka S, Rogler G, Fournier N, Pittet V, Scharl M, Greuter T, Schreiner P, Frei P, Misselwitz B, Biedermann L, Zeitz J; Swiss IBD Cohort Study Group. Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study. PLoS One 2019;14:e0215738. [PMID: 31022217 DOI: 10.1371/journal.pone.0215738] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Ricciardelli C, Zampaletta C, Elisei W, Picchio M. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol 2019;32:392-9. [PMID: 31263362 DOI: 10.20524/aog.2019.0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
93 Omotehara S, Nishida M, Kinoshita K, Onishi R, Onodera A, Suya M, Hasegawa T, Mitsumori D, Katsurada T, Teshima T. Validation of US evaluation of ulcerative colitis activity. Ultrasound Med Biol 2019;45:1537-44. [PMID: 30987912 DOI: 10.1016/j.ultrasmedbio.2019.02.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
94 Mañosa M, Chaparro M, Juan A, Aràjol C, Alfaro I, Mínguez M, Velayos B, Benítez J, Mesonero F, Sicilia B, Zabana Y, Villoria A, Gisbert J, Domènech E; on behalf of the ENEIDA registry by GETECCU. Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers. Am J Gastroenterol 2019;114:771-6. [DOI: 10.14309/ajg.0000000000000210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
95 Probert F, Walsh A, Jagielowicz M, Yeo T, Claridge TDW, Simmons A, Travis S, Anthony DC. Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis. J Crohns Colitis 2018;12:1326-37. [PMID: 30016408 DOI: 10.1093/ecco-jcc/jjy101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
96 He Q. Cardiocerebral and peripheral vascular risks in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2019; 27(5): 341-346 [DOI: 10.11569/wcjd.v27.i5.341] [Reference Citation Analysis]
97 Jackson B, Begun J, Gray K, Churilov L, Liew D, Knowles S, De Cruz P. Clinical decision support improves quality of care in patients with ulcerative colitis. Aliment Pharmacol Ther 2019;49:1040-51. [DOI: 10.1111/apt.15209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
98 Taha ME, Abdalla A, Al-Khafaji J, Malik S. Mesalamine-Induced Myopericarditis: A Case Report and Literature Review. Cardiol Res 2019;10:59-62. [PMID: 30834061 DOI: 10.14740/cr820] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
99 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 91] [Article Influence: 16.7] [Reference Citation Analysis]
100 Bank S, Julsgaard M, Abed OK, Burisch J, Broder Brodersen J, Pedersen NK, Gouliaev A, Ajan R, Nytoft Rasmussen D, Honore Grauslund C, Roug S, Galsgaard J, Sprogøe Høyer Finsen D, Lindby K, Sørensen J, Larsen L, Rohr Andersen M, Brandslund I, Thomassen M, Green A, Bo Bojesen A, Bek Sørensen S, Vogel U, Andersen V; Danish IBD Genetics Working Group. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:890-903. [PMID: 30811631 DOI: 10.1111/apt.15187] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
101 Ahmad H, Kumar VL. Pharmacotherapy of ulcerative colitis - current status and emerging trends. J Basic Clin Physiol Pharmacol 2018;29:581-92. [PMID: 30089097 DOI: 10.1515/jbcpp-2016-0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
102 Ben-Horin S, Zhao Y, Guo J, Mao R, Novack L, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Colombel JF, Peyrin-Biroulet L, Kaplan G, Chen MH. Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. BMJ Open 2019;9:e024222. [PMID: 30782731 DOI: 10.1136/bmjopen-2018-024222] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
103 Qiu Y, Chen B, Li Y, Xiong S, Zhang S, He Y, Zeng Z, Ben-Horin S, Chen M, Mao R. Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study. BMC Gastroenterol 2019;19:7. [PMID: 30630426 DOI: 10.1186/s12876-018-0928-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
104 Wu HM, Wei J, Li J, Wang K, Ye L, Qi Y, Yuan BS, Yang YL, Zhao L, Yang Z, Yang MF, Gong JF, Wang FY. Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis. Dig Dis Sci 2019;64:3263-73. [PMID: 30604378 DOI: 10.1007/s10620-018-5446-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
105 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 783] [Article Influence: 170.5] [Reference Citation Analysis]
106 Danese S, Bonovas S, Peyrin-Biroulet L. Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile. J Crohns Colitis 2017;11:767-8. [PMID: 28333203 DOI: 10.1093/ecco-jcc/jjx025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Tagawa M, Nakamura Y, Okura Y, Nanba H, Kishi K, Akashi E, Ochiai Y, Asai Y, Chinushi M. Successful Treatment of Acute Fulminant Eosinophilic Myocarditis in a Patient with Ulcerative Colitis Using Steroid Therapy and Percutaneous Cardiopulmonary Support. Intern Med 2019;58:1111-8. [PMID: 30568130 DOI: 10.2169/internalmedicine.1528-18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Na SY, Moon W. [Evolving Therapeutic Strategies in the Inflammatory Bowel Disease]. Korean J Gastroenterol 2018;71:61-8. [PMID: 29471602 DOI: 10.4166/kjg.2018.71.2.61] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
109 Scharnhorst V, Schmitz EMH, van de Kerkhof D, Derijks LJJ, Broeren MAC. A value proposition for trough level-based anti-TNFα drug dosing. Clin Chim Acta 2019;489:89-95. [PMID: 30521801 DOI: 10.1016/j.cca.2018.11.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
110 MacKenzie-Smith L, Marchi P, Thorne H, Timeus S, Young R, Le Calvé P. Patient Preference and Physician Perceptions of Patient Preference for Oral Pharmaceutical Formulations: Results from a Real-Life Survey. Inflamm Intest Dis 2018;3:43-51. [PMID: 30505842 DOI: 10.1159/000493346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
111 Takano R, Osawa S, Uotani T, Tani S, Ishida N, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Furuta T, Miyajima H, Sugimoto K. Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission. World J Clin Cases 2018; 6(15): 952-960 [PMID: 30568951 DOI: 10.12998/wjcc.v6.i15.952] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
112 Kinoshita K, Katsurada T, Nishida M, Omotehara S, Onishi R, Mabe K, Onodera A, Sato M, Eto K, Suya M, Maemoto A, Hasegawa T, Yamamoto J, Mitsumori D, Yoshii S, Ono K, Sakamoto N. Usefulness of transabdominal ultrasonography for assessing ulcerative colitis: a prospective, multicenter study. J Gastroenterol 2019;54:521-9. [DOI: 10.1007/s00535-018-01534-w] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
113 Bernerth K, Schiefke I, Liebscher K, Raczynski S, Kottmann T, Teich N. Factor-XIII activity in patients with mild to moderate ulcerative colitis and active bleeding: a prospective observational study. BMC Res Notes 2018;11:853. [PMID: 30514356 DOI: 10.1186/s13104-018-3963-8] [Reference Citation Analysis]
114 Melo M, Nunes R, Sarmento B, das Neves J. Rectal administration of nanosystems: from drug delivery to diagnostics. Materials Today Chemistry 2018;10:128-41. [DOI: 10.1016/j.mtchem.2018.09.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
115 Хіміон ЛВ, Данилюк СВ, Кіча НВ, Будько ТМ. Nonspecific Ulcerative Colitis in Practice of Family Doctor. СМ 2018;0:5-9. [DOI: 10.30841/2307-5112.5.2018.163902] [Reference Citation Analysis]
116 Jain S, Kedia S, Bopanna S, Yadav DP, Goyal S, Sahni P, Dash NR, Pal S, Makharia G, Ahuja V. Left-sided colitis and extensive colitis have similar colectomy rates after index episode of acute severe colitis: A long-term follow-up study: Disease extent and acute severe colitis. JGH Open 2017;1:134-9. [DOI: 10.1002/jgh3.12023] [Reference Citation Analysis]
117 Belousova EA, Abdulganieva DI, Alexeeva OP, Alexeenko SA, Baranovsky AY, Valuyskikh EY, Golovenko AO, Golovenko OV, Zhigalova TN, Knyazev OV, Kulyapin AV, Lakhin AV, Livzan MA, Lubyanskaya TG, Nikolaeva NN, Nikitina NV, Nikulina IV, Osipenko MF, Pavlenko VV, Parfenov AI, Rogachikov YE, Svetlova IO, Tkachev AV, Tkachenko EI, Khalif IL, Chashkova EY, Shchukina OB, Yazenok NS, Yakovlev AA. Social and demographic characteristics, features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies. Alʹm klin med 2018;46:445-63. [DOI: 10.18786/2072-0505-2018-46-5-445-463] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
118 Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol 2018;12:1079-100. [PMID: 30284911 DOI: 10.1080/17474124.2018.1530109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
119 Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; Swiss IBD Cohort Study Group. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. Eur J Gastroenterol Hepatol 2018;30:612-20. [PMID: 29384798 DOI: 10.1097/MEG.0000000000001078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
120 Atreya R, Reinisch W, Peyrin-biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, Neurath MF, Hawkey C. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Digestive and Liver Disease 2018;50:1019-29. [DOI: 10.1016/j.dld.2018.06.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
121 Gerner RR, Klepsch V, Macheiner S, Arnhard K, Adolph TE, Grander C, Wieser V, Pfister A, Moser P, Hermann-Kleiter N, Baier G, Oberacher H, Tilg H, Moschen AR. NAD metabolism fuels human and mouse intestinal inflammation. Gut 2018;67:1813-23. [PMID: 28877980 DOI: 10.1136/gutjnl-2017-314241] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 14.8] [Reference Citation Analysis]
122 Mezzina N, Campbell Davies SE, Ardizzone S. Nonbiological therapeutic management of ulcerative colitis. Expert Opinion on Pharmacotherapy 2018;19:1747-57. [DOI: 10.1080/14656566.2018.1525361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
123 Youssef T, Saleh SA, Rund A, Montasser I, Mohsen M, Hazem O. Evaluation of interleukin 23 (IL-23) as a non-invasive test of disease severity in patients with ulcerative colitis. Arab J Gastroenterol 2018;19:116-20. [PMID: 30268427 DOI: 10.1016/j.ajg.2018.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
124 Tursi A, Elisei W, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Mocci G, Penna A, Rodino' S, Sebkova L, de Medici A, Pranzo G, Ricciardelli C, Grasso G, Scorza S, Zampaletta C, Picchio M. Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers. Medicine (Baltimore) 2018;97:e11897. [PMID: 30142791 DOI: 10.1097/MD.0000000000011897] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
125 Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman SN, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM. Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia. Nutrients. 2018;10. [PMID: 30200405 DOI: 10.3390/nu10091192] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
126 Maria-Ferreira D, Nascimento AM, Cipriani TR, Santana-Filho AP, Watanabe PDS, Sant Ana DMG, Luciano FB, Bocate KCP, van den Wijngaard RM, Werner MFP, Baggio CH. Rhamnogalacturonan, a chemically-defined polysaccharide, improves intestinal barrier function in DSS-induced colitis in mice and human Caco-2 cells. Sci Rep 2018;8:12261. [PMID: 30115942 DOI: 10.1038/s41598-018-30526-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
127 Wang Y, Tang Q, Duan P, Yang L. Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis. Immunopharmacol Immunotoxicol 2018;40:476-82. [PMID: 30111198 DOI: 10.1080/08923973.2018.1469145] [Cited by in Crossref: 21] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
128 Willemze RA, Bakker T, Pippias M, Ponsioen CY, de Jonge WJ. β-Blocker use is associated with a higher relapse risk of inflammatory bowel disease: a Dutch retrospective case-control study. Eur J Gastroenterol Hepatol 2018;30:161-6. [PMID: 29111997 DOI: 10.1097/MEG.0000000000001016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
129 Eriksson C, Henriksson I, Brus O, Zhulina Y, Nyhlin N, Tysk C, Montgomery S, Halfvarson J. Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study. Aliment Pharmacol Ther. 2018;48:638-645. [PMID: 30069892 DOI: 10.1111/apt.14920] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
130 Chang JY, Cheon JH, Park Y, Park SJ, Kim TI, Kim WH. Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation? Dig Dis Sci 2018;63:3041-8. [PMID: 29987626 DOI: 10.1007/s10620-018-5193-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
131 Opstelten JL, de Vries JHM, Wools A, Siersema PD, Oldenburg B, Witteman BJM. Dietary intake of patients with inflammatory bowel disease: A comparison with individuals from a general population and associations with relapse. Clin Nutr. 2019;38:1892-1898. [PMID: 30049516 DOI: 10.1016/j.clnu.2018.06.983] [Cited by in Crossref: 26] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
132 Reinisch W, Colombel J, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflammatory Bowel Diseases 2019;25:163-71. [DOI: 10.1093/ibd/izy229] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
133 Aniwan S, Harmsen WS, Tremaine WJ, Kane SV, Loftus EV Jr. Overall and Cause-Specific Mortality of Inflammatory Bowel Disease in Olmsted County, Minnesota, From 1970 Through 2016. Mayo Clin Proc. 2018;93:1415-1422. [PMID: 30293558 DOI: 10.1016/j.mayocp.2018.03.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
134 Tajti J, Látos M, Farkas K, Ábrahám S, Simonka Z, Paszt A, Molnár T, Lázár G. Effect of Laparoscopic Surgery on Quality of Life in Ulcerative Colitis. Journal of Laparoendoscopic & Advanced Surgical Techniques 2018;28:833-8. [DOI: 10.1089/lap.2017.0698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
135 Barbaro MR, Fuschi D, Cremon C, Carapelle M, Dino P, Marcellini MM, Dothel G, De Ponti F, Stanghellini V, Barbara G. Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators. Neurogastroenterol Motil 2018;30:e13388. [DOI: 10.1111/nmo.13388] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
136 Dan A, Boutros M, Nedjar H, Kopylov U, Afif W, Khalil MA, Rahme E. Cost of Ulcerative Colitis in Quebec, Canada: A Retrospective Cohort Study. Inflamm Bowel Dis 2017;23:1262-71. [PMID: 28691933 DOI: 10.1097/MIB.0000000000001147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
137 Yoon SM, Haritunians T, Chhina S, Liu Z, Yang S, Landers C, Li D, Ye BD, Shih D, Vasiliauskas EA, Ippoliti A, Rabizadeh S, Targan SR, Melmed GY, McGovern DPB. Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD. Inflamm Bowel Dis 2017;23:1382-93. [PMID: 28590340 DOI: 10.1097/MIB.0000000000001150] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
138 Jain S, Kedia S, Bopanna S, Sachdev V, Sahni P, Dash NR, Pal S, Vishnubhatla S, Makharia G, Travis SPL, Ahuja V. Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study. J Crohns Colitis. 2017;11:1309-1316. [PMID: 29088461 DOI: 10.1093/ecco-jcc/jjx084] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
139 Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis 2017;11:1317-25. [PMID: 28981846 DOI: 10.1093/ecco-jcc/jjx093] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
140 Jain S, Kedia S, Sethi T, Bopanna S, Yadav DP, Goyal S, Padhan R, Venigalla PM, Sahni P, Dash NR, Pal S, Makharia G, Travis SPL, Ahuja V. Predictors of long-term outcomes in patients with acute severe colitis: A northern Indian cohort study. J Gastroenterol Hepatol. 2018;33:615-622. [PMID: 28801987 DOI: 10.1111/jgh.13921] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
141 Bryant RV, Costello SP, Schoeman S, Sathananthan D, Knight E, Lau SY, Schoeman MN, Mountifield R, Tee D, Travis SPL, Andrews JM. Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice. J Gastroenterol Hepatol. 2018;33:599-607. [PMID: 28806471 DOI: 10.1111/jgh.13923] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
142 Wisniewski A, Fléjou JF, Siproudhis L, Abramowitz L, Svrcek M, Beaugerie L. Anal Neoplasia in Inflammatory Bowel Disease: Classification Proposal, Epidemiology, Carcinogenesis, and Risk Management Perspectives. J Crohns Colitis 2017;11:1011-8. [PMID: 28379306 DOI: 10.1093/ecco-jcc/jjx035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
143 Magnusson MK, Lasson A, Stridsberg M, Isaksson S, Strid H, Öhman L, Wei J. Faecal secretogranin and chromogranin levels persist over time and are unrelated to disease history and outcome in patients with ulcerative colitis. Cogent Medicine 2018;5:1484602. [DOI: 10.1080/2331205x.2018.1484602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Sanchez-Hernandez JG, Rebollo N, Munoz F, Martin-Suarez A, Calvo MV. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases. Ann Clin Biochem 2019;56:28-41. [PMID: 29807436 DOI: 10.1177/0004563218782286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
145 Bossuyt P, Baert F, D’heygere F, Nakad A, Reenaers C, Fontaine F, Franchimont D, Dewit O, Van Hootegem P, Vanden Branden S, Lambrecht G, Ferrante M, Hindryckx P, Macken E, Caenepeel P, Vijverman A, Suray ND, Dutré J, Louis E, Coenegracths J; Belgian IBD Research and Development Group. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. Inflammatory Bowel Diseases 2019;25:156-62. [DOI: 10.1093/ibd/izy219] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
146 Meijer B, Seinen ML, van Egmond R, Bouma G, Mulder CJJ, van Bodegraven AA, de Boer NKH. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication? Inflamm Bowel Dis 2017;23:2011-7. [PMID: 28617756 DOI: 10.1097/MIB.0000000000001168] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
147 So J, Tang W, Leung WK, Li M, Lo FH, Wong MTL, Sze ASF, Leung CM, Tsang SWC, Shan EHS, Chan KH, Lam BCY, Hui AJ, Chow WH, Lam TY, Lam V, Lee TW, Lo HHH, Tang CM, Wong CL, Wu JCY, Chan FKL, Sung JJY, Harbord M, Ng SC. Cancer Risk in 2621 Chinese Patients with Inflammatory Bowel Disease: A Population-based Cohort Study. Inflamm Bowel Dis 2017;23:2061-8. [PMID: 28991855 DOI: 10.1097/MIB.0000000000001240] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
148 Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017;11:785-791. [PMID: 28333362 DOI: 10.1093/ecco-jcc/jjx032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
149 Woo DH, Kim KO, Kang MK, Lee SH, Jang BI, Kim TN. Predictors and clinical outcomes of follow-up loss in patients with inflammatory bowel disease. J Gastroenterol Hepatol 2018;33:1834-8. [PMID: 29664147 DOI: 10.1111/jgh.14258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Vavricka SR, Heinrich H, Buetikofer S, Breitenmoser F, Burri E, Schneider-Yin X, Barman-Aksoezen J, Biedermann L, Scharl M, Zeitz J, Rogler G, Misselwitz B, Sauter M. The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding. United European Gastroenterol J 2018;6:1007-14. [PMID: 30228888 DOI: 10.1177/2050640618774416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
151 Cannon AR, Kuprys PV, Cobb AN, Ding X, Kothari AN, Kuo PC, Eberhardt JM, Hammer AM, Morris NL, Li X, Choudhry MA. Alcohol enhances symptoms and propensity for infection in inflammatory bowel disease patients and a murine model of DSS-induced colitis. J Leukoc Biol 2018;104:543-55. [PMID: 29775230 DOI: 10.1002/JLB.4MA1217-506R] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
152 Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol 2018;31:572-82. [PMID: 30174394 DOI: 10.20524/aog.2018.0276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
153 Bressler B, Williamson M, Sattin B, Camacho F, Steinhart AH. Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure. J Can Assoc Gastroenterol. 2018;1:129-134. [PMID: 31294354 DOI: 10.1093/jcag/gwy019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
154 Niepel D, Klag T, Malek NP, Wehkamp J. Practical guidance for the management of iron deficiency in patients with inflammatory bowel disease. Therap Adv Gastroenterol 2018;11:1756284818769074. [PMID: 29760784 DOI: 10.1177/1756284818769074] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
155 Cristina T, Carmen AA, Luana A, Eugen D. Inflammatory Bowel Diseases: Focus on Therapy. ARS Medica Tomitana 2018;24:9-14. [DOI: 10.2478/arsm-2018-0003] [Reference Citation Analysis]
156 Bähler C, Schoepfer AM, Vavricka SR, Brüngger B, Reich O. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol 2017;29:916-25. [PMID: 28471826 DOI: 10.1097/MEG.0000000000000891] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
157 Meijer B, Wilhelm AJ, Mulder CJJ, Bouma G, van Bodegraven AA, de Boer NKH. Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study. Ther Drug Monit. 2017;39:399-405. [PMID: 28489727 DOI: 10.1097/ftd.0000000000000414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
158 Gregor JC, Williamson M, Dajnowiec D, Sattin B, Sabot E, Salh B. Inflammatory bowel disease patients prioritize mucosal healing, symptom control, and pain when choosing therapies: results of a prospective cross-sectional willingness-to-pay study. Patient Prefer Adherence 2018;12:505-13. [PMID: 29692603 DOI: 10.2147/PPA.S152872] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
159 Nahon S, Lahmek P, Macaigne G, Lesgourgues B, Paupard T. Crohn's disease treatment practices in France in1999-2013: A prospective survey in non-academic hospitals. Clin Res Hepatol Gastroenterol 2018;42:470-7. [PMID: 29625924 DOI: 10.1016/j.clinre.2018.03.004] [Reference Citation Analysis]
160 Ribiere S, Leconte M, Chaussade S, Abitbol V. [Acute severe colitis]. Presse Med 2018;47:312-9. [PMID: 29618409 DOI: 10.1016/j.lpm.2018.02.020] [Reference Citation Analysis]
161 Miele E, Shamir R, Aloi M, Assa A, Braegger C, Bronsky J, de Ridder L, Escher JC, Hojsak I, Kolaček S, Koletzko S, Levine A, Lionetti P, Martinelli M, Ruemmele F, Russell RK, Boneh RS, van Limbergen J, Veereman G, Staiano A. Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Journal of Pediatric Gastroenterology & Nutrition 2018;66:687-708. [DOI: 10.1097/mpg.0000000000001896] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 14.8] [Reference Citation Analysis]
162 Kovacs G, Sipeki N, Suga B, Tornai T, Fechner K, Norman GL, Shums Z, Antal-Szalmas P, Papp M. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients. PLoS One 2018;13:e0194166. [PMID: 29590158 DOI: 10.1371/journal.pone.0194166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
163 Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, Nørgård B. The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1011-8. [PMID: 28346274 DOI: 10.1097/MIB.0000000000001102] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
164 Ananthakrishnan AN, Donaldson T, Lasch K, Yajnik V. Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. Inflamm Bowel Dis. 2017;23:882-893. [PMID: 28375885 DOI: 10.1097/mib.0000000000001099] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
165 Laurent V, Naudé S, Vuitton L, Zallot C, Baumann C, Girard-Gavanier M, Peyrin-Biroulet L. Accuracy of Diffusion-weighted Magnetic Resonance Colonography in Assessing Mucosal Healing and the Treatment Response in Patients with Ulcerative Colitis. J Crohns Colitis 2017;11:716-23. [PMID: 27932450 DOI: 10.1093/ecco-jcc/jjw211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
166 Carlsen A, Omdal R, Leitao KØ, Isaksen K, Hetta AK, Karlsen LN, Aabakken L, Bolstad N, Warren D, Lundin KEA, Grimstad T. Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease. Therap Adv Gastroenterol 2018;11:1756284818759930. [PMID: 29623105 DOI: 10.1177/1756284818759930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
167 Prieux-Klotz C, Dior M, Damotte D, Dreanic J, Brieau B, Brezault C, Abitbol V, Chaussade S, Coriat R. Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. Target Oncol 2017;12:301-8. [PMID: 28540478 DOI: 10.1007/s11523-017-0495-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 10.5] [Reference Citation Analysis]
168 Altwegg R, Combes R, Laharie D, De Ledinghen V, Radenne S, Conti F, Chazouilleres O, Duvoux C, Dumortier J, Leroy V, Treton X, Durand F, Dharancy S, Nachury M, Goutorbe F, Lamblin G, Boivineau L, Peyrin-Biroulet L, Pageaux GP. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. Dig Liver Dis. 2018;50:668-674. [PMID: 29655972 DOI: 10.1016/j.dld.2018.02.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
169 Chen L, Gao Y, Zhang Z, Sun M, Yang W, Liu Z, Jiang X. Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or -resistant ulcerative colitis patients. Oncotarget 2018;9:15027-35. [PMID: 29599923 DOI: 10.18632/oncotarget.24541] [Reference Citation Analysis]
170 Dignass A, Akbar A, Baumgart DC, Bommelaer G, Bouguen G, Cadiot G, Gillessen A, Grimaud JC, Hart A, Hoque S, Makins R, Michiels C, Moreau J, Premchand P, Ramlow W, Schanz S, Subramanian S, von Tirpitz C, Bonaz B. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scand J Gastroenterol. 2018;53:442-448. [PMID: 29513111 DOI: 10.1080/00365521.2018.1447598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
171 Boeing T, de Souza P, Bonomini TJ, Mariano LNB, Somensi LB, Lucinda RM, Malheiros A, da Silva LM, Andrade SFD. Antioxidant and anti-inflammatory effect of plumieride in dextran sulfate sodium-induced colitis in mice. Biomedicine & Pharmacotherapy 2018;99:697-703. [DOI: 10.1016/j.biopha.2018.01.142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
172 Jeuring SFG, Biemans VBC, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDSL Cohort. American Journal of Gastroenterology 2018;113:384-95. [DOI: 10.1038/ajg.2017.482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
173 Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Gradel KO, Friedman S, Nørgård BM. Fecal Calprotectin During Pregnancy in Women With Moderate-Severe Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:839-48. [DOI: 10.1093/ibd/izx055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
174 Monk JM, Wu W, Hutchinson AL, Pauls P, Robinson LE, Power KA. Navy and black bean supplementation attenuates colitis-associated inflammation and colonic epithelial damage. J Nutr Biochem 2018;56:215-23. [PMID: 29631142 DOI: 10.1016/j.jnutbio.2018.02.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
175 Rubin DT, Dubinsky MC, Martino S, Hewett KA, Panés J. Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. Inflamm Bowel Dis 2017;23:494-501. [PMID: 28296817 DOI: 10.1097/MIB.0000000000001048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
176 Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2017;23:570-577. [PMID: 28230558 DOI: 10.1097/mib.0000000000001049] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 16.8] [Reference Citation Analysis]
177 Jeuring SF, van den Heuvel TR, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, Oostenbrug LE, Masclee AA, Jonkers DM, Pierik MJ. Epidemiology and Long-term Outcome of Inflammatory Bowel Disease Diagnosed at Elderly Age-An Increasing Distinct Entity? Inflamm Bowel Dis 2016;22:1425-34. [PMID: 26933752 DOI: 10.1097/MIB.0000000000000738] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 21.3] [Reference Citation Analysis]
178 Brandse JF, Bennink RJ, van Eeden S, Löwenberg M, van den Brink GR, DʼHaens GR. Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1384-90. [PMID: 26978724 DOI: 10.1097/MIB.0000000000000746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
179 Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J, Jonaitis L, Dilger K, Nacak T, Greinwald R; International SAT-25 Study Group. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterol J. 2018;6:138-147. [PMID: 29435324 DOI: 10.1177/2050640617703842,] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20:1-326. [PMID: 27220829 DOI: 10.3310/hta20390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
181 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 252] [Cited by in F6Publishing: 214] [Article Influence: 63.0] [Reference Citation Analysis]
182 Baillet P, Cadiot G, Goutte M, Goutorbe F, Brixi H, Hoeffel C, Allimant C, Reymond M, Obritin-Guilhen H, Magnin B, Bommelaer G, Pereira B, Hordonneau C, Buisson A. Faecal calprotectin and magnetic resonance imaging in detecting Crohn’s disease endoscopic postoperative recurrence. World J Gastroenterol 2018; 24(5): 641-650 [PMID: 29434453 DOI: 10.3748/wjg.v24.i5.641] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
183 Burrello C, Garavaglia F, Cribiù FM, Ercoli G, Bosari S, Caprioli F, Facciotti F. Short-term Oral Antibiotics Treatment Promotes Inflammatory Activation of Colonic Invariant Natural Killer T and Conventional CD4+ T Cells. Front Med (Lausanne) 2018;5:21. [PMID: 29468162 DOI: 10.3389/fmed.2018.00021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
184 Nikolaus S, Schreiber S, Siegmund B, Bokemeyer B, Bästlein E, Bachmann O, Görlich D, Hofmann U, Schwab M, Kruis W. Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence. J Crohns Colitis 2017;11:1052-62. [PMID: 28486634 DOI: 10.1093/ecco-jcc/jjx062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
185 Bosworth BP, Sandborn WJ, Rubin DT, Harper JR. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis 2016;22:1881-6. [PMID: 27416045 DOI: 10.1097/MIB.0000000000000860] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
186 Manetti N, Bagnoli S, Rogai F, Bonanomi AG, Vannozzi G, Giannotta M, Annese V. Disease Course and Colectomy Rate of Ulcerative Colitis: A Follow-up Cohort Study of a Referral Center in Tuscany. Inflamm Bowel Dis 2016;22:1945-53. [PMID: 27104823 DOI: 10.1097/MIB.0000000000000787] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
187 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Fumery M, Carbonnel F, Bommelaer G, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Lambert J, Mary JY, Louis E; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018;67:237-43. [PMID: 28053054 DOI: 10.1136/gutjnl-2016-313060] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 21.8] [Reference Citation Analysis]
188 Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: When? How? Best Practice & Research Clinical Gastroenterology 2018;32-33:71-8. [DOI: 10.1016/j.bpg.2018.05.017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
189 Fabisiak N, Fabisiak A, Watala C, Fichna J. Fat-soluble Vitamin Deficiencies and Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2017;51:878-889. [PMID: 28858940 DOI: 10.1097/mcg.0000000000000911] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
190 Caneparo V, Pastorelli L, Pisani LF, Bruni B, Prodam F, Boldorini R, Roggenbuck D, Vecchi M, Landolfo S, Gariglio M, De Andrea M. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy. Inflamm Bowel Dis. 2016;22:2977-2987. [PMID: 27636380 DOI: 10.1097/mib.0000000000000926] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
191 Degenhardt F, Dirmeier A, Lopez R, Lang S, Kunst C, Roggenbuck D, Reinhold D, Szymczak S, Rogler G, Klebl F, Franke A, Rieder F. Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease. Inflamm Bowel Dis. 2016;22:2648-2657. [PMID: 27753692 DOI: 10.1097/mib.0000000000000936] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
192 Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X17750355. [PMID: 29383030 DOI: 10.1177/1756283x17750355] [Cited by in Crossref: 90] [Cited by in F6Publishing: 104] [Article Influence: 22.5] [Reference Citation Analysis]
193 Derwa Y, Williams CJM, Sood R, Mumtaz S, Bholah MH, Selinger CP, Hamlin PJ, Ford AC, Gracie DJ. Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. Therap Adv Gastroenterol. 2018;11:1756283X17744739. [PMID: 29383026 DOI: 10.1177/1756283x17744739] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
194 Jain S, Kedia S, Bopanna S, Yadav DP, Goyal S, Sahni P, Pal S, Dash NR, Makharia G, Travis SPL, Ahuja V. Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. Intest Res 2018;16:69-74. [PMID: 29422800 DOI: 10.5217/ir.2018.16.1.69] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
195 Lobatón T, Bessissow T, Ruiz-Cerulla A, De Hertogh G, Bisschops R, Guardiola J, Van Assche G, Vermeire S, Ferrante M. Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study. United European Gastroenterol J 2018;6:765-72. [PMID: 30083339 DOI: 10.1177/2050640617752207] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
196 Bálint A, Farkas K, Szepes Z, Nagy F, Szűcs M, Tiszlavicz L, Bor R, Milassin Á, Rutka M, Fábián A, Molnár T. How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system. BMC Gastroenterol 2018;18:7. [PMID: 29310593 DOI: 10.1186/s12876-017-0725-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
197 Angelino G, De Angelis P, Faraci S, Rea F, Romeo EF, Torroni F, Tambucci R, Claps A, Francalanci P, Chiriaco M, Di Matteo G, Cancrini C, Palma P, D'argenio P, Dall'oglio L, Rossi P, Finocchi A. Inflammatory bowel disease in chronic granulomatous disease: An emerging problem over a twenty years' experience. Pediatr Allergy Immunol 2017;28:801-9. [DOI: 10.1111/pai.12814] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
198 Cassieri C, Brandimarte G, Elisei W, Lecca GP, Goni E, Penna A, Picchio M, Tursi A. How to Differentiate Segmental Colitis Associated With Diverticulosis and Inflammatory Bowel Diseases. J Clin Gastroenterol. 2016;50 Suppl 1:S36-S38. [PMID: 27622359 DOI: 10.1097/mcg.0000000000000630] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
199 Bähler C, Vavricka SR, Schoepfer AM, Brüngger B, Reich O. Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. BMC Gastroenterol 2017;17:138. [PMID: 29197335 DOI: 10.1186/s12876-017-0681-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
200 Selinger CP, Lenti MV, Clark T, Rafferty H, Gracie D, Ford AC, Oʼconnor A, Ahmad T, Hamlin PJ. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:2083-8. [DOI: 10.1097/mib.0000000000001258] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
201 Armuzzi A, Felice C, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Marchesoni A, Vecchi M, Olivieri I. Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. Digestive and Liver Disease 2017;49:1298-305. [DOI: 10.1016/j.dld.2017.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
202 Meijer B, Seinen ML, Leijte NN, Mulder CJ, van Bodegraven AA, de Boer NK. Clinical Value of Mercaptopurine After Failing Azathioprine Therapy in Patients With Inflammatory Bowel Disease. Ther Drug Monit. 2016;38:463-470. [PMID: 27158876 DOI: 10.1097/ftd.0000000000000312] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
203 Meijer B, Kreijne JE, van Moorsel SAW, Derijks LJJ, Bouma G, Mulder CJJ, Wong DR, van der Woude CJ, van Bodegraven AA, de Boer NKH. 6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients. J Gastroenterol Hepatol 2017;32:1183-90. [PMID: 27859568 DOI: 10.1111/jgh.13656] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
204 Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9:65-72. [PMID: 29387331 DOI: 10.1177/2040622317742095] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
205 Zhang Z, Yang L, Wang B, Zhang L, Zhang Q, Li D, Zhang S, Gao H, Wang X. Protective role of liriodendrin in mice with dextran sulphate sodium-induced ulcerative colitis. International Immunopharmacology 2017;52:203-10. [DOI: 10.1016/j.intimp.2017.09.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
206 Kammerlander H, Nielsen J, Knudsen T, Kjeldsen J, Friedman S, Nørgård BM. Anti–TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate–severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight: . Inflammatory Bowel Diseases 2017;23:1916-23. [DOI: 10.1097/mib.0000000000001234] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
207 Helmy AM, Elsabahy M, Soliman GM, Mahmoud MA, Ibrahim EA. Development and in vivo evaluation of chitosan beads for the colonic delivery of azathioprine for treatment of inflammatory bowel disease. European Journal of Pharmaceutical Sciences 2017;109:269-79. [DOI: 10.1016/j.ejps.2017.08.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
208 Lew D, Yoon SM, Yan X, Robbins L, Haritunians T, Liu Z, Li D, McGovern DP. Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients. World J Gastroenterol 2017; 23(40): 7265-7273 [PMID: 29142473 DOI: 10.3748/wjg.v23.i40.7265] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
209 Scaldaferri F, D'Ambrosio D, Holleran G, Poscia A, Petito V, Lopetuso L, Graziani C, Laterza L, Pistone MT, Pecere S, Currò D, Gaetani E, Armuzzi A, Papa A, Cammarota G, Gasbarrini A. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. PLoS One 2017;12:e0186575. [PMID: 29073159 DOI: 10.1371/journal.pone.0186575] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
210 Rouiller-Braunschweig C, Fournier N, Pittet V, Dudler J, Michetti P. Efficacy, Safety and Mucosal Healing of Methotrexate in a Large Longitudinal Cohort of Inflammatory Bowel Disease Patients. Digestion 2017;96:220-7. [PMID: 29065423 DOI: 10.1159/000482007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
211 Lee WS, Azmi N, Ng RT, Ong SY, Ponnampalavanar SS, Mahadeva S, Hilmi I. Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy. Intest Res 2017;15:524-8. [PMID: 29142521 DOI: 10.5217/ir.2017.15.4.524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
212 McIlroy J, Ianiro G, Mukhopadhya I, Hansen R, Hold GL. Review article: The gut microbiome in inflammatory bowel disease-avenues for microbial management. Aliment Pharmacol Ther. 2018;47:26-42. [PMID: 29034981 DOI: 10.1111/apt.14384] [Cited by in Crossref: 114] [Cited by in F6Publishing: 109] [Article Influence: 22.8] [Reference Citation Analysis]
213 Ahmad H, Verma S, Kumar VL. Effect of roxithromycin on mucosal damage, oxidative stress and pro-inflammatory markers in experimental model of colitis. Inflamm Res 2018;67:147-55. [PMID: 28988395 DOI: 10.1007/s00011-017-1103-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
214 Meijer B, van Everdingen CK, Ramsoekh D, Stedman C, Frampton CMA, Mulder CJJ, Bouma G, de Boer NKH, Gearry RB. Transient elastography to assess liver stiffness in patients with inflammatory bowel disease. Dig Liver Dis 2018;50:48-53. [PMID: 29050997 DOI: 10.1016/j.dld.2017.09.128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
215 Cross RK. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:1689-701. [DOI: 10.1097/mib.0000000000001261] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
216 Toyonaga T, Kobayashi T, Nakano M, Saito E, Umeda S, Okabayashi S, Ozaki R, Hibi T. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLoS One 2017;12:e0185131. [PMID: 28934315 DOI: 10.1371/journal.pone.0185131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
217 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
218 Ardesia M, Costantino G, Mondello P, Alibrandi A, Fries W. Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy. Gastroenterol Res Pract 2017;2017:4139656. [PMID: 29075289 DOI: 10.1155/2017/4139656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
219 Parker B, Buchanan J, Wordsworth S, Keshav S, George B, East JE. Surgery versus surveillance in ulcerative colitis patients with endoscopically invisible low-grade dysplasia: a cost-effectiveness analysis. Gastrointest Endosc 2017;86:1088-1099.e5. [PMID: 28882578 DOI: 10.1016/j.gie.2017.08.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
220 Shinzaki S, Iijima H, Fujii H, Kamada Y, Naka T, Takehara T, Miyoshi E. A novel pathogenesis of inflammatory bowel disease from the perspective of glyco-immunology. J Biochem 2017;161:409-15. [PMID: 28338836 DOI: 10.1093/jb/mvx010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
221 Asl Baakhtari S, Mccombie A, ten Bokkel Huinink S, Irving P, Siegel CA, Mulder R, Mulder CJ, Gearry R. Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids. Dig Dis 2017;36:33-9. [DOI: 10.1159/000478772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
222 Jitsumura M, Kokelaar RF, Harris DA. Remission endpoints in ulcerative colitis: A systematic review. World J Meta-Anal 2017; 5(4): 85-102 [DOI: 10.13105/wjma.v5.i4.85] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
223 Majumdar I, Ahuja V, Paul J. Altered expression of Tumor Necrosis Factor Alpha -Induced Protein 3 correlates with disease severity in Ulcerative Colitis. Sci Rep 2017;7:9420. [PMID: 28842689 DOI: 10.1038/s41598-017-09796-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
224 Frieri G, Galletti B, Di Ruscio M, Tittoni R, Capannolo A, Serva D, Latella G, Sollima L, Leocata P, Necozione S, Frieri R, Viscido A. The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine. Therap Adv Gastroenterol 2017;10:749-59. [PMID: 29051786 DOI: 10.1177/1756283X17722926] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
225 Qiao YQ, Cai CW, Ran ZH. Therapeutic modulation of gut microbiota in inflammatory bowel disease: More questions to be answered. J Dig Dis. 2016;17:800-810. [PMID: 27743467 DOI: 10.1111/1751-2980.12422] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
226 Głąbska D, Guzek D, Grudzińska D, Lech G. Influence of dietary isoflavone intake on gastrointestinal symptoms in ulcerative colitis individuals in remission. World J Gastroenterol 2017; 23(29): 5356-5363 [PMID: 28839435 DOI: 10.3748/wjg.v23.i29.5356] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
227 Naganuma M, Aoyama N, Tada T, Kobayashi K, Hirai F, Watanabe K, Watanabe M, Hibi T. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. J Gastroenterol 2018;53:494-506. [PMID: 28779419 DOI: 10.1007/s00535-017-1376-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
228 Greish K, Taha S, Jasim A, Elghany SA, Sultan A, AlKhateeb A, Othman M, Jun F, Taurin S, Bakhiet M. Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease. Clin Transl Med 2017;6:28. [PMID: 28770521 DOI: 10.1186/s40169-017-0157-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
229 Zeitz J, Bissig M, Barthel C, Biedermann L, Scharl S, Pohl D, Frei P, Vavricka SR, Fried M, Rogler G, Scharl M. Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease? Eur J Gastroenterol Hepatol. 2017;29:322-330. [PMID: 27879485 DOI: 10.1097/meg.0000000000000783] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
230 Fascì-Spurio F, Meucci G, Papi C, Saibeni S; IG-IBD (Italian Group for Inflammatory Bowel Disease). The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey. Dig Liver Dis 2017;49:1092-7. [PMID: 28801181 DOI: 10.1016/j.dld.2017.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
231 Shi HY, Chan FKL, Higashimori A, Kyaw M, Ching JYL, Chan HCH, Chan JCH, Chan AWH, Lam KLY, Tang RSY. A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). Gastrointest Endosc. 2017;86:1139-1146.e6. [PMID: 28713062 DOI: 10.1016/j.gie.2017.07.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
232 Shi HY, Chan FKL, Chan AWH, Higashimori A, Kyaw M, Ching JYL, Luk AKC, Wong SH, Wu JCY, Sung JJY, Ng SC. Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores. Journal of Crohn's and Colitis 2017;11:1071-7. [DOI: 10.1093/ecco-jcc/jjx088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
233 Dart RJ, Irving PM. Optimising use of thiopurines in inflammatory bowel disease. Expert Review of Clinical Immunology 2017;13:877-88. [DOI: 10.1080/1744666x.2017.1351298] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
234 Aggarwal S, Ahuja V, Paul J. Attenuated GABAergic Signaling in Intestinal Epithelium Contributes to Pathogenesis of Ulcerative Colitis. Dig Dis Sci. 2017;62:2768-2779. [PMID: 28667430 DOI: 10.1007/s10620-017-4662-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
235 Calafat M, Lobatón T, Mañosa M, Marín L, Caballero N, Larraín M, Cabré E, Domènech E. Therapeutic requirements in active ulcerative proctitis: A single-centre study. Gastroenterol Hepatol 2017;40:663-8. [PMID: 28666605 DOI: 10.1016/j.gastrohep.2017.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
236 Sullivan KJ, Wei M, Chernetsova E, Hallani S, de Nanassy J, Benchimol EI, Mack DR, Nasr A, El Demellawy D. Value of upper endoscopic biopsies in predicting medical refractoriness in pediatric patients with ulcerative colitis. Hum Pathol. 2017;66:167-176. [PMID: 28652148 DOI: 10.1016/j.humpath.2017.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
237 Shih I, Wei S, Yen R, Chang C, Ko C, Lin B, Shun C, Liu K, Wong J, Chang Y. PET/MRI for evaluating subclinical inflammation of ulcerative colitis: PET/MRI in Ulcerative Colitis. J Magn Reson Imaging 2018;47:737-45. [DOI: 10.1002/jmri.25795] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
238 Kim ES, Kim KO, Jang BI, Kim EY, Lee YJ, Lee HS, Jeon SW, Kim HJ, Kim SK; Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD). Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis. Dig Dis Sci 2017;62:2489-97. [PMID: 28639128 DOI: 10.1007/s10620-017-4634-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
239 Troncone E, Monteleone G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin Drug Saf 2017;16:779-89. [PMID: 28608717 DOI: 10.1080/14740338.2017.1340936] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
240 Biedermann L. Vancomycin in Very-Early Onset Inflammatory Bowel Disease-Dysbiosis: Fight Fire with Fire? Digestion 2017;95:327-8. [PMID: 28609775 DOI: 10.1159/000477088] [Reference Citation Analysis]
241 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Intest Res. 2017;15:266-284. [PMID: 28670225 DOI: 10.5217/ir.2017.15.3.266] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
242 Ogata H, Ohori A, Nishino H, Mizushima S, Hagino A, Hibi T. Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study. Intest Res 2017;15:358-67. [PMID: 28670233 DOI: 10.5217/ir.2017.15.3.358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
243 Ogata H, Aoyama N, Mizushima S, Hagino A, Hibi T. Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study. Intest Res 2017;15:368-79. [PMID: 28670234 DOI: 10.5217/ir.2017.15.3.368] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
244 Abolfotouh S, Rautio T, Klintrup K, Helavirta I, Mäkelä J. Predictors of quality-of-life after ileal pouch-anal anastomosis in patients with ulcerative colitis. Scand J Gastroenterol 2017;52:1078-85. [PMID: 28599590 DOI: 10.1080/00365521.2017.1337218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
245 Kim S, Lee B, Zhang X, Park J, Lee S, Lee H. Adjunctive herbal medicine therapy for inflammatory bowel disease: A systematic review and meta-analysis. European Journal of Integrative Medicine 2017;12:12-22. [DOI: 10.1016/j.eujim.2017.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
246 D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther 2017;46:292-302. [PMID: 28568974 DOI: 10.1111/apt.14164] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
247 Kanters TA, Stevanovic J, Huys I, Vulto AG, Simoens S. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. Front Pharmacol. 2017;8:322. [PMID: 28620302 DOI: 10.3389/fphar.2017.00322] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
248 Ierardi E, Losurdo G, Iannone A, Piscitelli D, Amoruso A, Barone M, Principi M, Pisani A, Di Leo A. Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored? Ann Gastroenterol. 2017;30:380-392. [PMID: 28655974 DOI: 10.20524/aog.2017.0165] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
249 Puri AS, Desai D, Sood A, Sachdeva S. Infliximab‐induced tuberculosis in patients with UC: Experience from India—a country with high prevalence of tuberculosis. Journal of Gastroenterology and Hepatology 2017;32:1191-4. [DOI: 10.1111/jgh.13669] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
250 Macaluso FS, Renna S, Maida M, Dimarco M, Sapienza C, Affronti M, Orlando E, Rizzuto G, Orlando R, Ventimiglia M, Cottone M, Orlando A. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. Scandinavian Journal of Gastroenterology 2017. [DOI: 10.1080/00365521.2017.1333626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
251 Nardelli S, Pisani LF, Tontini GE, Vecchi M, Pastorelli L. MMX® technology and its applications in gastrointestinal diseases. Therap Adv Gastroenterol 2017;10:545-52. [PMID: 28804515 DOI: 10.1177/1756283X17709974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
252 Chaparro M, Ramas M, Benítez JM, López-García A, Juan A, Guardiola J, Mínguez M, Calvet X, Márquez L, Fernández Salazar LI, Bujanda L, García C, Zabana Y, Lorente R, Barrio J, Hinojosa E, Iborra M, Cajal MD, Van Domselaar M, García-Sepulcre MF, Gomollón F, Piqueras M, Alcaín G, García-Sánchez V, Panés J, Domènech E, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry. Am J Gastroenterol 2017;112:1135-43. [PMID: 28534520 DOI: 10.1038/ajg.2017.96] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
253 Kalappurayil NB, Thomas J, Mankuni B, Thomas V. Assessment of Disease Severity and Role of Cytomegalo Virus Infection in Patients with Ulcerative Colitis. J Clin Diagn Res 2017;11:EC07-11. [PMID: 28511386 DOI: 10.7860/JCDR/2017/22816.9332] [Reference Citation Analysis]
254 Bonovas S, Fiorino G, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply. Aliment Pharmacol Ther 2017;45:1554-5. [PMID: 28503864 DOI: 10.1111/apt.14084] [Reference Citation Analysis]
255 Andersen V, Holmskov U, Sørensen SB, Jawhara M, Andersen KW, Bygum A, Hvid L, Grauslund J, Wied J, Glerup H, Fredberg U, Villadsen JA, Kjær SG, Fallingborg J, Moghadd SAGR, Knudsen T, Brodersen J, Frøjk J, Dahlerup JF, Nielsen OH, Christensen R, Bojesen AB, Sorensen GL, Thiel S, Færgeman NJ, Brandslund I, Stensballe A, Schmidt EB, Franke A, Ellinghaus D, Rosenstiel P, Raes J, Heitmann B, Boye M, Nielsen CL, Werner L, Kjeldsen J, Ellingsen T. A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine. Nutrients 2017;9:E499. [PMID: 28505128 DOI: 10.3390/nu9050499] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
256 Filipec Kanizaj T, Mijic M. Inflammatory bowel disease in liver transplanted patients. World J Gastroenterol 2017; 23(18): 3214-3227 [PMID: 28566881 DOI: 10.3748/wjg.v23.i18.3214] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
257 Kokkinidis DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, Texakalidis PT, Economopoulos KP, Kousoulis AA. Emerging treatments for ulcerative colitis: a systematic review. Scand J Gastroenterol 2017;52:923-31. [PMID: 28503977 DOI: 10.1080/00365521.2017.1326163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
258 Gordon M. 5-Aminosalicylates to maintain remission in Crohn’s disease: Interpreting conflicting systematic review evidence. World J Gastrointest Pharmacol Ther 2017; 8(2): 99-102 [PMID: 28533918 DOI: 10.4292/wjgpt.v8.i2.99] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
259 Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Review of Clinical Pharmacology 2017;10:595-607. [DOI: 10.1080/17512433.2017.1318062] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
260 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
261 Chu TPC, Moran GW, Card TR. The Pattern of Underlying Cause of Death in Patients with Inflammatory Bowel Disease in England: A Record Linkage Study. J Crohns Colitis 2017;11:578-85. [PMID: 28453767 DOI: 10.1093/ecco-jcc/jjw192] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
262 Gerçeker E, Yüceyar H, Kasap E, Demirci U, Ekti BC, Aydoğdu İ, Miskioğlu M. Treatment of inflammatory bowel disease by leukocytapheresis. Transfus Apher Sci 2017;56:421-6. [PMID: 28454883 DOI: 10.1016/j.transci.2017.03.016] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
263 Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, Karmiris K, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har-Noy O, Bernstein CN. Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice. World J Gastroenterol 2017; 23(16): 2995-3002 [PMID: 28522918 DOI: 10.3748/wjg.v23.i16.2995] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
264 Brückner M, Heidemann J, Nowacki TM, Cordes F, Stypmann J, Lenz P, Gohar F, Lügering A, Bettenworth D. Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound. World J Gastroenterol 2017; 23(16): 2899-2911 [PMID: 28522908 DOI: 10.3748/wjg.v23.i16.2899] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
265 Yarygin K, Tyakht A, Larin A, Kostryukova E, Kolchenko S, Bitner V, Alexeev D. Abundance profiling of specific gene groups using precomputed gut metagenomes yields novel biological hypotheses. PLoS One 2017;12:e0176154. [PMID: 28448616 DOI: 10.1371/journal.pone.0176154] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
266 van den Heuvel TRA, Jeuring SFG, Zeegers MP, van Dongen DHE, Wolters A, Masclee AAM, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Pierik MJ, Jonkers DM. A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort—Can Diagnostic Factors Explain the Increase in IBD Incidence? Journal of Crohn's and Colitis 2017;11:1169-79. [DOI: 10.1093/ecco-jcc/jjx055] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
267 Boal Carvalho P, Cotter J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs. 2017;77:159-173. [PMID: 28078646 DOI: 10.1007/s40265-016-0676-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
268 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
269 Dignass A, Schnabel R, Romatowski J, Pavlenko V, Dorofeyev A, Derova J, Jonaitis L, Dilger K, Nacak T, Greinwald R; International SAT-25 Study Group. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial. United European Gastroenterol J 2018;6:138-47. [PMID: 29435324 DOI: 10.1177/2050640617703842] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
270 Squires SI, Boal AJ, Lamont S, Naismith GD. Implementing a self-management strategy in inflammatory bowel disease (IBD): patient perceptions, clinical outcomes and the impact on service. Frontline Gastroenterol 2017;8:272-8. [PMID: 29067153 DOI: 10.1136/flgastro-2017-100807] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
271 Szandruk M, Merwid-Ląd A, Szeląg A. The impact of mangiferin from Belamcanda chinensis on experimental colitis in rats. Inflammopharmacology 2018;26:571-81. [PMID: 28337639 DOI: 10.1007/s10787-017-0337-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
272 Levine A, Yerushalmi B, Kori M, Broide E, Mozer-glassberg Y, Shaoul R, Kolho K, Shteyer E, Shamaly H, Ledder O, Cohen S, Peleg S, Shabat CS, Focht G, Shachmon E, Boaz M, On A, Turner D. Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study. Journal of Crohn's and Colitis 2017;11:970-4. [DOI: 10.1093/ecco-jcc/jjx042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
273 Zeng J, Lv L, Mei Z. Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis: Budesonide foam for ulcerative colitis. Journal of Gastroenterology and Hepatology 2017;32:558-66. [DOI: 10.1111/jgh.13604] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
274 Simian D, Flores L, Quera R, Kronberg U, Ibáñez P, Figueroa C, Lubascher J. Assessment of disease-related knowledge and possible factors associated with the knowledge level among Chilean patients with inflammatory bowel disease. J Clin Nurs 2017;26:1508-15. [PMID: 27322103 DOI: 10.1111/jocn.13436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
275 Andersen V, Hansen AK, Heitmann BL. Potential Impact of Diet on Treatment Effect from Anti-TNF Drugs in Inflammatory Bowel Disease. Nutrients 2017;9:E286. [PMID: 28294972 DOI: 10.3390/nu9030286] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
276 Jiang X, Karlsen TH. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol 2017;14:279-95. [DOI: 10.1038/nrgastro.2016.154] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 12.2] [Reference Citation Analysis]
277 Schmitz EM, van de Kerkhof D, Hamann D, van Dongen JL, Kuijper PH, Brunsveld L, Scharnhorst V, Broeren MA. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits. Clin Chem Lab Med 2016;54:1211-9. [PMID: 26587745 DOI: 10.1515/cclm-2015-0987] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
278 Testa A, Castiglione F, Nardone OM, Colombo GL. Adherence in ulcerative colitis: an overview. Patient Prefer Adherence 2017;11:297-303. [PMID: 28260866 DOI: 10.2147/PPA.S127039] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
279 Kristensen V, Lauritzen T, Jelsness-Jørgensen LP, Frigstad SO, Corwin C, Moum B. Patient-performed extraction of faecal calprotectin. Clin Chem Lab Med 2016;54:1357-63. [PMID: 26812797 DOI: 10.1515/cclm-2015-1037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
280 Olivera P, Danese S, Peyrin-biroulet L. JAK inhibition in inflammatory bowel disease. Expert Review of Clinical Immunology 2017;13:693-703. [DOI: 10.1080/1744666x.2017.1291342] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 9.2] [Reference Citation Analysis]
281 Kawakami A, Tanaka M, Naganuma M, Maeda S, Kunisaki R, Yamamoto-Mitani N. What strategies do ulcerative colitis patients employ to facilitate adherence? Patient Prefer Adherence 2017;11:157-63. [PMID: 28203059 DOI: 10.2147/PPA.S117841] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
282 Bezzio C, Festa S, Saibeni S, Papi C. Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence. Expert Review of Gastroenterology & Hepatology 2017;11:339-47. [DOI: 10.1080/17474124.2017.1292129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
283 Mantzaris GJ. Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. Curr Treat Options Gastro 2017;15:84-104. [DOI: 10.1007/s11938-017-0128-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
284 Macaluso FS, Maida M, Renna S, Orlando E, Affronti M, Sapienza C, Dimarco M, Orlando R, Rizzuto G, Cottone M, Orlando A. Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants. Digestive and Liver Disease 2017;49:157-62. [DOI: 10.1016/j.dld.2016.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
285 Lenti MV, Selinger CP. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Rev Gastroenterol Hepatol 2017;11:215-26. [PMID: 28099821 DOI: 10.1080/17474124.2017.1284587] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
286 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
287 Jackson BD, Con D, Liew D, De Cruz P. Clinicians’ adherence to international guidelines in the clinical care of adults with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2017;52:536-42. [DOI: 10.1080/00365521.2017.1278785] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
288 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
289 Amezaga AJ, Van Assche G. Practical Approaches to "Top-Down" Therapies for Crohn's Disease. Curr Gastroenterol Rep 2016;18:35. [PMID: 27184044 DOI: 10.1007/s11894-016-0507-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
290 Franceschet I, Cazzagon N, Del Ross T, D'Incà R, Buja A, Floreani A. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options. Eur J Gastroenterol Hepatol 2016;28:508-13. [PMID: 26872110 DOI: 10.1097/MEG.0000000000000596] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
291 Monteiro S, Dias de Castro F, Boal Carvalho P, Rosa B, Moreira MJ, Pinho R, Saraiva MM, Cotter J. Essential role of small bowel capsule endoscopy in reclassification of colonic inflammatory bowel disease type unclassified. World J Gastrointest Endosc 2017; 9(1): 34-40 [PMID: 28101306 DOI: 10.4253/wjge.v9.i1.34] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
292 Campos ST, Portela FA, Tomé L. Cytomegalovirus, inflammatory bowel disease, and anti-TNFα. Int J Colorectal Dis 2017;32:645-50. [DOI: 10.1007/s00384-017-2752-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
293 Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory Bowel Disease. Dtsch Arztebl Int 2016;113:72-82. [PMID: 26900160 DOI: 10.3238/arztebl.2016.0072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
294 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
295 Kawakami A, Tanaka M, Ochiai R, Naganuma M, Kunisaki R, Kazuma K. Difficulties in Performing Mesalazine Enemas and Factors Related to Discontinuation Among Patients With Ulcerative Colitis: . Gastroenterology Nursing 2017;40:101-8. [DOI: 10.1097/sga.0000000000000147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
296 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
297 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
298 Forbes A, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, Bischoff SC. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr 2017;36:321-47. [PMID: 28131521 DOI: 10.1016/j.clnu.2016.12.027] [Cited by in Crossref: 254] [Cited by in F6Publishing: 279] [Article Influence: 42.3] [Reference Citation Analysis]
299 Prosberg MV, Vester-Andersen MK, Andersson M, Jess T, Andersen JT, Vind I, Bendtsen F. Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study. Inflamm Bowel Dis 2016;22:925-32. [PMID: 26818426 DOI: 10.1097/MIB.0000000000000700] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
300 Lee HS, Park SH, Kim SH, Kim J, Choi J, Lee HJ, Kim WS, Lee JM, Kwak MS, Hwang SW, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH, Yang SK. Risk Factors and Clinical Outcomes Associated with Cytomegalovirus Colitis in Patients with Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2016;22:912-8. [PMID: 26829410 DOI: 10.1097/MIB.0000000000000675] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
301 Fornaro R, Caratto E, Caratto M, Sticchi C, Salerno A, Bianchi R, Scabini S, Casaccia M. Surgery of acute severe ulcerative colitis. Subtotal colectomy: when and how to do it? Eur Surg 2017;49:108-12. [DOI: 10.1007/s10353-016-0458-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
302 Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22(47): 10432-10439 [PMID: 28058024 DOI: 10.3748/wjg.v22.i47.10432] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
303 Gisbert JP, Barreiro-de Acosta M, Esteve M, García-Sánchez V, Gomollón F, Guardiola J, Hinojosa J, Martín Arranz MD, Minguez M, Taxonera C, Vera I. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project. Inflamm Bowel Dis 2016;22:583-98. [PMID: 26529561 DOI: 10.1097/MIB.0000000000000617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
304 Bodelier AG, Jonkers D, van den Heuvel T, de Boer E, Hameeteman W, Masclee AA, Pierik MJ. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score. Dig Dis Sci. 2017;62:465-472. [PMID: 27933473 DOI: 10.1007/s10620-016-4397-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
305 Di Girolamo M, Sartini A, Critelli R, Bertani A, Merighi A, Villa E. Efficacy of a Novel Granulocyte Monocyte Apheresis Adsorber Device in the Treatment of Inflammatory Bowel Diseases: A Pilot Study. Ther Apher Dial 2016;20:668-76. [PMID: 27921374 DOI: 10.1111/1744-9987.12453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
306 Deiana S, Bagnoli S, Manetti N, Caini S, Giannotta M, Scaringi S, Annese V. Outcome of acute severe ulcerative colitis in patients previously exposed to immunosuppressive therapy. Digestive and Liver Disease 2016;48:1432-7. [DOI: 10.1016/j.dld.2016.07.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
307 Regueiro MD, Greer JB, Hanauer SB. Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. Am J Gastroenterol Suppl 2016;3:8-16. [DOI: 10.1038/ajgsup.2016.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
308 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 1116] [Article Influence: 138.3] [Reference Citation Analysis]
309 Bączyk G, Formanowicz D, Gmerek Ł, Krokowicz P. Health-related quality of life assessment among patients with inflammatory bowel diseases after surgery - review. Prz Gastroenterol 2017;12:6-16. [PMID: 28337230 DOI: 10.5114/pg.2016.64037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
310 Lopetuso LR, Petito V, Zinicola T, Graziani C, Gerardi V, Arena V, Caristo ME, Poscia A, Cammarota G, Papa A, Cufino V, Sgambato A, Gasbarrini A, Scaldaferri F. Infliximab does not increase colonic cancer risk associated to murine chronic colitis. World J Gastroenterol 2016; 22(44): 9727-9733 [PMID: 27956796 DOI: 10.3748/wjg.v22.i44.9727] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
311 Prieux-Klotz C, Nahon S, Amiot A, Sinayoko L, Galéano-Cassaz C, Chaussade S, Coriat R, Lahmek P, Abitbol V. Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study. Dig Dis Sci 2017;62:473-80. [PMID: 27853898 DOI: 10.1007/s10620-016-4374-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
312 Manguso F, Bennato R, Lombardi G, Riccio E, Costantino G, Fries W. Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0166455. [PMID: 27846307 DOI: 10.1371/journal.pone.0166455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
313 Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clin Pharmacokinet. 2016;55:257-274. [PMID: 26255287 DOI: 10.1007/s40262-015-0316-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
314 Meijer B, Mulder CJ, van Bodegraven AA, de Boer NKH. How I treat my inflammatory bowel disease-patients with thiopurines? World J Gastrointest Pharmacol Ther 2016; 7(4): 524-530 [PMID: 27867685 DOI: 10.4292/wjgpt.v7.i4.524] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
315 Ianiro G, Tilg H, Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 2016;65:1906-15. [PMID: 27531828 DOI: 10.1136/gutjnl-2016-312297] [Cited by in Crossref: 281] [Cited by in F6Publishing: 262] [Article Influence: 46.8] [Reference Citation Analysis]
316 Collij V, Festen EAM, Alberts R, Weersma RK. Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information: . Inflammatory Bowel Diseases 2016;22:2562-70. [DOI: 10.1097/mib.0000000000000912] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
317 Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK. Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review. World J Gastroenterol 2016; 22(40): 9012-9021 [PMID: 27833392 DOI: 10.3748/wjg.v22.i40.9012] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
318 Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F, Dray-spira R. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014. Aliment Pharmacol Ther 2017;45:37-49. [DOI: 10.1111/apt.13835] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 9.3] [Reference Citation Analysis]
319 Currò D, Ianiro G, Pecere S, Bibbò S, Cammarota G. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol 2017;174:1426-49. [PMID: 27696378 DOI: 10.1111/bph.13632] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 10.5] [Reference Citation Analysis]
320 Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N, Sebastian S, Rizzello F, Limdi J, Katsanos K, Schmidt C, Jeuring S, Colombo F, Gionchetti P. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. J Crohns Colitis 2017;11:263-73. [PMID: 27797918 DOI: 10.1093/ecco-jcc/jjw188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
321 Viazis N, Giakoumis M, Bamias G, Goukos D, Koukouratos T, Katopodi K, Karatzas P, Triantos C, Tsolias C, Theocharis G, Daikos GL, Ladas SD, Karamanolis DG, Mantzaris GJ. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF. Dig Liver Dis 2017;49:29-33. [PMID: 27866814 DOI: 10.1016/j.dld.2016.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
322 Fornaro R, Caratto M, Barbruni G, Fornaro F, Salerno A, Giovinazzo D, Sticchi C, Caratto E. Surgical and medical treatment in patients with acute severe ulcerative colitis. J Dig Dis. 2015;16:558-567. [PMID: 26315728 DOI: 10.1111/1751-2980.12278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
323 Yu Q, Mao R, Lian L, Ng SC, Zhang S, Chen Z, Zhang Y, Qiu Y, Chen B, He Y, Zeng Z, Ben-Horin S, Song X, Chen M. Surgical management of inflammatory bowel disease in China: a systematic review of two decades. Intest Res 2016;14:322-32. [PMID: 27799883 DOI: 10.5217/ir.2016.14.4.322] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
324 Jang HW, Kim HS, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease. Intest Res 2016;14:305-13. [PMID: 27799881 DOI: 10.5217/ir.2016.14.4.305] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
325 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
326 Panes J, Jairath V, Levesque BG. Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. Gastroenterology. 2017;152:362-373.e3. [PMID: 27751880 DOI: 10.1053/j.gastro.2016.10.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
327 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
328 Makker J, Hommes DW. Etrolizumab for ulcerative colitis: the new kid on the block? Expert Opin Biol Ther. 2016;16:567-572. [PMID: 26914639 DOI: 10.1517/14712598.2016.1158807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
329 Guan LF, Hu BW, Sun L, Lian F, Liu TT. Dynamic management and therapeutic strategy for inflammatory bowel disease in pregnancy. Shijie Huaren Xiaohua Zazhi 2016; 24(28): 3978-3984 [DOI: 10.11569/wcjd.v24.i28.3978] [Reference Citation Analysis]
330 Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol 2016;9:329-36. [DOI: 10.1007/s12328-016-0686-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
331 Samak YO, El Massik M, Coombes AGA. A Comparison of Aerosolization and Homogenization Techniques for Production of Alginate Microparticles for Delivery of Corticosteroids to the Colon. J Pharm Sci 2017;106:208-16. [PMID: 27693300 DOI: 10.1016/j.xphs.2016.08.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
332 Andrew RE, Messaris E. Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new? World J Gastrointest Surg 2016; 8(9): 598-605 [PMID: 27721922 DOI: 10.4240/wjgs.v8.i9.598] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
333 D'haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther 2016;44:1018-29. [DOI: 10.1111/apt.13803] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
334 Wahid AM, Devarajan K, Ross A, Zilbauer M, Heuschkel R. Paediatric gastrointestinal endoscopy: a qualitative study. Eur J Gastroenterol Hepatol. 2016;28:25-29. [PMID: 26473298 DOI: 10.1097/meg.0000000000000488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
335 Ward MG, Kariyawasam VC, Mogan SB, Patel KV, Pantelidou M, Sobczyńska-Malefora A, Porté F, Griffin N, Anderson SH, Sanderson JD, Harrington DJ, Irving PM. Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's Disease. Inflamm Bowel Dis 2015;21:2839-47. [PMID: 26296064 DOI: 10.1097/MIB.0000000000000559] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
336 Bonnaud G, Haennig A, Levy J, Sigur N, Ledit A, Cabarrot P, Faure P, Auzimour C, El Atmani A, Hebuterne X, Peyrin-Biroulet L. Implementation of the French national consensus for the management of ulcerative colitis into clinical practice. Dig Liver Dis 2016;48:1405-9. [PMID: 27697417 DOI: 10.1016/j.dld.2016.08.127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
337 Stansfield C. Considerations in the management of ulcerative colitis. Gastrointestinal Nursing 2016;14:42-50. [DOI: 10.12968/gasn.2016.14.7.42] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
338 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 11.2] [Reference Citation Analysis]
339 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 19.0] [Reference Citation Analysis]
340 Grossi E, Melli S, Dunca D, Terruzzi V. Unexpected improvement in core autism spectrum disorder symptoms after long-term treatment with probiotics. SAGE Open Med Case Rep 2016;4:2050313X16666231. [PMID: 27621806 DOI: 10.1177/2050313X16666231] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
341 Peyrin-biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther 2016;44:807-16. [DOI: 10.1111/apt.13763] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 13.3] [Reference Citation Analysis]
342 Kedia S, Ahuja V, Makharia GK. Golimumab for moderately to severely active ulcerative colitis. Expert Rev Clin Pharmacol 2016;9:1273-82. [PMID: 27498886 DOI: 10.1080/17512433.2016.1221759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
343 Rispo A, Testa A, De Palma GD, Donetto S, Diaferia M, Musto D, Nardone O, Maione F, Caporaso N, Castiglione F. Different Profile of Efficacy of Thiopurines in Ulcerative Colitis and Crohn’s Disease. Inflamm Bowel Dis. 2015;21:2570-2575. [PMID: 26222340 DOI: 10.1097/mib.0000000000000538] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
344 Ward MG, Patel KV, Kariyawasam VC, Goel R, Warner B, Elliott TR, Blaker PA, Irving PM, Marinaki AM, Sanderson JD. Thioguanine in inflammatory bowel disease: Long-term efficacy and safety. United European Gastroenterol J 2017;5:563-70. [PMID: 28588888 DOI: 10.1177/2050640616663438] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
345 Lui RNS, Ng SC. The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West? Inflamm Intest Dis 2016;1:78-84. [PMID: 29922661 DOI: 10.1159/000446625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
346 Bek S, Nielsen JV, Bojesen AB, Franke A, Bank S, Vogel U, Andersen V. Systematic review: Genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;44:554-567. [PMID: 27417569 DOI: 10.1111/apt.13736] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 11.3] [Reference Citation Analysis]
347 Muhvić-Urek M, Tomac-Stojmenović M, Mijandrušić-Sinčić B. Oral pathology in inflammatory bowel disease. World J Gastroenterol 2016; 22(25): 5655-5667 [PMID: 27433081 DOI: 10.3748/wjg.v22.i25.5655] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 45] [Article Influence: 8.7] [Reference Citation Analysis]
348 Pouillon L, Bossuyt P, Peyrin-Biroulet L. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opin Biol Ther. 2016;16:1277-1290. [PMID: 27329436 DOI: 10.1080/14712598.2016.1203897] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
349 Chhaya V, Saxena S, Cecil E, Subramanian V, Curcin V, Majeed A, Pollok RC. Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study. Aliment Pharmacol Ther 2016;44:482-94. [DOI: 10.1111/apt.13700] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
350 Barreiro-de Acosta M, Gisbert JP. Letter: anti-TNF in steroid-dependent ulcerative colitis - are the available data enough? Aliment Pharmacol Ther 2016;44:102. [PMID: 27250593 DOI: 10.1111/apt.13646] [Reference Citation Analysis]
351 Drabik A, Sturm A, Blömacher M, Helwig U. Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study. JMIR Res Protoc 2016;5:e124. [PMID: 27352964 DOI: 10.2196/resprot.5791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
352 Lin CC, Wei SC, Lin BR, Tsai WS, Chen JS, Hsu TC, Lin WC, Huang TY, Chao TH, Lin HH, Wong JM, Lin JK. A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease. Intest Res 2016;14:248-57. [PMID: 27433147 DOI: 10.5217/ir.2016.14.3.248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
353 Bager P, Julsgaard M, Vestergaard T, Christensen LA, Dahlerup JF. Adherence and quality of care in IBD. Scand J Gastroenterol 2016;51:1326-31. [PMID: 27311071 DOI: 10.1080/00365521.2016.1195870] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
354 Iskandar HN, Dhere T, Farraye FA. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015;17:44. [PMID: 26386686 DOI: 10.1007/s11894-015-0466-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
355 Stansfield C. Inflammatory bowel disease: current challenges and advances in treatment. British Journal of Healthcare Management 2016;22:300-3. [DOI: 10.12968/bjhc.2016.22.6.300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
356 Orlando A, Renna S, Rizzuto G, Orlando E, Affronti M, Cottone M. Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center. Clinical Gastroenterology and Hepatology 2016;14:914. [DOI: 10.1016/j.cgh.2015.12.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
357 van den Heuvel TR, Wintjens DS, Jeuring SF, Wassink MH, Romberg-Camps MJ, Oostenbrug LE, Sanduleanu S, Hameeteman WH, Zeegers MP, Masclee AA, Jonkers DM, Pierik MJ. Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer 2016;139:1270-80. [PMID: 27170593 DOI: 10.1002/ijc.30183] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
358 Samaan MA, Irving PM. The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future. Expert Opin Biol Ther 2016;16:975-7. [PMID: 27186809 DOI: 10.1080/14712598.2016.1189529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
359 Chaparro M, Gisbert JP. Maintenance therapy options for ulcerative colitis. Expert Opinion on Pharmacotherapy 2016;17:1339-49. [DOI: 10.1080/14656566.2016.1187132] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
360 Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Büning C; AEGIS Study Group. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Aliment Pharmacol Ther 2016;44:259-70. [PMID: 27237709 DOI: 10.1111/apt.13665] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
361 Ferrari L, Krane MK, Fichera A. Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg 2016; 8(5): 363-370 [PMID: 27231514 DOI: 10.4240/wjgs.v8.i5.363] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
362 Qian J, Zhao W, Miao X, Li L, Zhang D. Sam68 modulates apoptosis of intestinal epithelial cells via mediating NF-κB activation in ulcerative colitis. Mol Immunol 2016;75:48-59. [PMID: 27235792 DOI: 10.1016/j.molimm.2016.05.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
363 Iannazzo S, Furneri G, Demma F, Distante C, Parisi S, Berti V, Fusaro E. The Burden of Rheumatic Diseases: An Analysis of an Italian Administrative Database. Rheumatol Ther 2016;3:167-77. [PMID: 27747521 DOI: 10.1007/s40744-016-0034-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
364 Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
365 Magro F, Lopes SI, Lopes J, Portela F, Cotter J, Lopes S, Moreira MJ, Lago P, Peixe P, Albuquerque A, Rodrigues S, Silva MR, Monteiro P, Lopes C, Monteiro L, Macedo G, Veloso L, Camila C, Afonso J, Geboes K, Carneiro F; Portuguese IBD group [GEDII]. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. J Crohns Colitis 2016;10:1407-16. [PMID: 27226417 DOI: 10.1093/ecco-jcc/jjw112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
366 Vögelin M, Biedermann L, Frei P, Vavricka SR, Scharl S, Zeitz J, Sulz MC, Fried M, Rogler G, Scharl M. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PLoS One 2016;11:e0155218. [PMID: 27214202 DOI: 10.1371/journal.pone.0155218] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
367 Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson Å, Knittel T, Kowalski J, Lukas M, Löfberg R, Nancey S, Petryka R, Rydzewska G, Schnabel R, Seidler U, Neurath MF, Hawkey C. Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. J Crohns Colitis 2016;10:1294-302. [PMID: 27208386 DOI: 10.1093/ecco-jcc/jjw103] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
368 Fiorino G, Gilardi D, Danese S. The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. Therap Adv Gastroenterol 2016;9:503-12. [PMID: 27366219 DOI: 10.1177/1756283X16647935] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
369 Knyazev OV, Parfenov AI, Konoplyannikov AG, Boldyreva ON. [Use of mesenchymal stem cells in the combination therapy of ulcerative colitis]. Ter Arkh 2016;88:44-8. [PMID: 27030183 DOI: 10.17116/terarkh201688244-48] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
370 To N, Ford AC, Gracie DJ. Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. Aliment Pharmacol Ther. 2016;44:117-126. [PMID: 27193202 DOI: 10.1111/apt.13663] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
371 Danese S, Hart A, Dignass A, Louis E, D'Haens G, Dotan I, Rogler G, D'Agay L, Iannacone C, Peyrin-Biroulet L. Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterol 2016;3:e000092. [PMID: 27239329 DOI: 10.1136/bmjgast-2016-000092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
372 Lee HS, Yang SK, Soh JS, Lee S, Bae JH, Lee HJ, Park SH, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH. Short- and Long-Term Outcomes of Acute Severe Ulcerative Colitis in Korea: The 1999-2005 Cohort. Inflamm Bowel Dis 2015;21:1825-31. [PMID: 25985248 DOI: 10.1097/MIB.0000000000000447] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
373 Ban H, Bamba S, Nishida A, Inatomi O, Shioya M, Takahashi KI, Imaeda H, Murata M, Sasaki M, Tsujikawa T, Andoh A. Prognostic factors affecting early colectomy in patients with moderate to severe ulcerative colitis treated with calcineurin inhibitors. Exp Ther Med. 2016;12:829-834. [PMID: 27446283 DOI: 10.3892/etm.2016.3341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
374 Wilburn J, Twiss J, Kemp K, McKenna SP. A qualitative study of the impact of Crohn's disease from a patient's perspective. Frontline Gastroenterol 2017;8:68-73. [PMID: 28839887 DOI: 10.1136/flgastro-2015-100678] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
375 Neumann PA, Rijcken E. Minimally invasive surgery for inflammatory bowel disease: Review of current developments and future perspectives. World J Gastrointest Pharmacol Ther 2016; 7(2): 217-226 [PMID: 27158537 DOI: 10.4292/wjgpt.v7.i2.217] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
376 Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AMM, Soria J, Mateus C, Robert C. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016;13:473-86. [DOI: 10.1038/nrclinonc.2016.58] [Cited by in Crossref: 491] [Cited by in F6Publishing: 545] [Article Influence: 81.8] [Reference Citation Analysis]
377 Thörn M, Rorsman F, Rönnblom A, Sangfelt P, Wanders A, Eriksson BM, Bondeson K. Active cytomegalovirus infection diagnosed by real-time PCR in patients with inflammatory bowel disease: a prospective, controlled observational study (.). Scand J Gastroenterol. 2016;51:1075-1080. [PMID: 27142339 DOI: 10.3109/00365521.2016.1156154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
378 Casellas F, Marín-jiménez I, Borruel N, Riestra S. Colitis ulcerosa en remisión: mejora de la adhesión terapéutica desde una perspectiva multidisciplinar. Enfermedad Inflamatoria Intestinal al Día 2016;15:37-43. [DOI: 10.1016/j.eii.2016.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
379 Fischer S, Neurath MF, Atreya R. [Colitis ulcerosa - a diagnostic and therapeutic update]. MMW Fortschr Med 2016;158:77-80. [PMID: 27116171 DOI: 10.1007/s15006-016-8152-x] [Reference Citation Analysis]
380 Ahmed O, Nguyen GC. Therapeutic challenges of managing inflammatory bowel disease in the elderly patient. Expert Rev Gastroenterol Hepatol 2016;10:1005-10. [PMID: 27087144 DOI: 10.1080/17474124.2016.1179579] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
381 Matijašić M, Meštrović T, Perić M, Čipčić Paljetak H, Panek M, Vranešić Bender D, Ljubas Kelečić D, Krznarić Ž, Verbanac D. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. Int J Mol Sci 2016;17:E578. [PMID: 27104515 DOI: 10.3390/ijms17040578] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
382 Shi HY, Chan FK, Leung WK, Li MK, Leung CM, Sze SF, Ching JY, Lo FH, Tsang SW, Shan EH, Mak LY, Lam BC, Hui AJ, Chow WH, Wong MT, Hung IF, Hui YT, Chan YK, Chan KH, Loo CK, Ng CK, Lao WC, Harbord M, Wu JC, Sung JJ, Ng SC. Low-dose azathioprine is effective in maintaining remission in steroid-dependent ulcerative colitis: results from a territory-wide Chinese population-based IBD registry. Therap Adv Gastroenterol. 2016;9:449-456. [PMID: 27366213 DOI: 10.1177/1756283x16643509] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
383 Kinugasa T, Akagi Y. Status of colitis-associated cancer in ulcerative colitis. World J Gastrointest Oncol 2016; 8(4): 351-357 [PMID: 27096030 DOI: 10.4251/wjgo.v8.i4.351] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
384 Jauregui-Amezaga A, Vermeire S, Prenen H. Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. Ann Gastroenterol 2016;29:127-36. [PMID: 27065724 DOI: 10.20524/aog.2016.0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
385 Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X. French national consensus clinical guidelines for the management of ulcerative colitis. Dig Liver Dis. 2016;48:726-733. [PMID: 27158125 DOI: 10.1016/j.dld.2016.03.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
386 Solina G, Mandalà S, La Barbera C, Mandalà V. Current management of intestinal bowel disease: the role of surgery. Updates Surg 2016;68:13-23. [PMID: 27067590 DOI: 10.1007/s13304-016-0361-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
387 Feuerstein JD, Akbari M, Tapper EB, Cheifetz AS. Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Ann Gastroenterol 2016;29:341-7. [PMID: 27366036 DOI: 10.20524/aog.2016.0032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
388 Llaó J, Naves JE, Ruiz-Cerulla A, Gordillo J, Mañosa M, Maisterra S, Cabré E, Garcia-Planella E, Guardiola J, Domènech E. Improved outcome of acute severe ulcerative colitis while using early predictors of corticosteroid failure and rescue therapies. Dig Liver Dis 2016;48:608-12. [PMID: 27012443 DOI: 10.1016/j.dld.2016.02.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
389 Pillet S, Jarlot C, Courault M, Del Tedesco E, Chardon R, Saint-Sardos P, Presles E, Phelip JM, Berthelot P, Pozzetto B, Roblin X. Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015;21:1580-1586. [PMID: 25933392 DOI: 10.1097/mib.0000000000000412] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
390 Aviello G, Knaus UG. ROS in gastrointestinal inflammation: Rescue Or Sabotage? Br J Pharmacol 2017;174:1704-18. [PMID: 26758851 DOI: 10.1111/bph.13428] [Cited by in Crossref: 78] [Cited by in F6Publishing: 100] [Article Influence: 13.0] [Reference Citation Analysis]
391 Blotière PO, Rudant J, Barré A, Racine A, Weill A, Peyrin-Biroulet L, Carbonnel F, Alla F. Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013). Dig Liver Dis. 2016;48:620-625. [PMID: 27017107 DOI: 10.1016/j.dld.2016.02.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
392 Steponaitiene R, Kupcinskas J, Survilaite S, Varkalaite G, Jonaitis L, Kiudelis G, Denapiene G, Valantinas J, Skieceviciene J, Kupcinskas L. TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects. Adv Med Sci 2016;61:135-40. [PMID: 26674571 DOI: 10.1016/j.advms.2015.09.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
393 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2016;65:408-14. [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598] [Cited by in Crossref: 219] [Cited by in F6Publishing: 210] [Article Influence: 36.5] [Reference Citation Analysis]
394 Assa A, Avni I, Ben-bassat O, Niv Y, Shamir R. Practice Variations in the Management of Inflammatory Bowel Disease Between Pediatric and Adult Gastroenterologists. Journal of Pediatric Gastroenterology & Nutrition 2016;62:372-7. [DOI: 10.1097/mpg.0000000000000943] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
395 Jackson BD, Gray K, Knowles SR, De Cruz P. EHealth Technologies in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2016;10:1103-21. [PMID: 26928960 DOI: 10.1093/ecco-jcc/jjw059] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 11.5] [Reference Citation Analysis]
396 Durchschein F, Petritsch W, Hammer HF. Diet therapy for inflammatory bowel diseases: The established and the new. World J Gastroenterol 2016; 22(7): 2179-2194 [PMID: 26900283 DOI: 10.3748/wjg.v22.i7.2179] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 68] [Article Influence: 15.7] [Reference Citation Analysis]
397 Kim JH, Cheon JH, Park Y, Lee HJ, Park SJ, Kim TI, Kim WH. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scand J Gastroenterol 2016;51:1069-74. [PMID: 26895215 DOI: 10.3109/00365521.2016.1150503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
398 Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, Harris R, Fadra AS, Basquill C, Lamb CA, Cameron FL, Murray CD, Parkes M, Gooding I, Ahmad T, Gaya DR, Mann S, Lindsay JO, Gordon J, Satsangi J, Hart A, McCartney S, Irving P, Lees CW; UK Anti-TNF withdrawal study group. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther 2016;43:910-23. [PMID: 26892328 DOI: 10.1111/apt.13547] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 10.3] [Reference Citation Analysis]
399 Hoy SM. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis. Drugs. 2015;75:879-886. [PMID: 25920500 DOI: 10.1007/s40265-015-0396-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
400 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
401 Langhorst J, Boone J, Lauche R, Rueffer A, Dobos G. Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. J Crohns Colitis 2016;10:786-94. [PMID: 26874351 DOI: 10.1093/ecco-jcc/jjw044] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
402 Safroneeva E, Vavricka SR, Fournier N, Straumann A, Rogler G, Schoepfer AM. Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. Inflamm Bowel Dis. 2015;21:1348-1358. [PMID: 25806845 DOI: 10.1097/mib.0000000000000368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
403 Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, Reinisch W. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111:477-491. [PMID: 26856754 DOI: 10.1038/ajg.2016.7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 15.0] [Reference Citation Analysis]
404 Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther 2016; 7(1): 5-20 [PMID: 26855808 DOI: 10.4292/wjgpt.v7.i1.5] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
405 Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 51-65 [PMID: 26855812 DOI: 10.4292/wjgpt.v7.i1.51] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
406 Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf. 2016;8:1-7. [PMID: 26893582 DOI: 10.2147/dhps.s62649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
407 Con D, De Cruz P. Mobile Phone Apps for Inflammatory Bowel Disease Self-Management: A Systematic Assessment of Content and Tools. JMIR Mhealth Uhealth. 2016;4:e13. [PMID: 26831935 DOI: 10.2196/mhealth.4874] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
408 Guiotto C, Daperno M, Frigerio F, Vizzini M, Cerruti R, Ercole E, Cosimato M, Lavagna A, Germano L, Migliardi M, Rocca R. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. Digestive and Liver Disease 2016;48:138-43. [DOI: 10.1016/j.dld.2015.10.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
409 Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. The gut microbiota and host health: a new clinical frontier. Gut 2016;65:330-9. [PMID: 26338727 DOI: 10.1136/gutjnl-2015-309990] [Cited by in Crossref: 1177] [Cited by in F6Publishing: 1091] [Article Influence: 196.2] [Reference Citation Analysis]
410 Shah ED, Siegel CA, Chong K, Melmed GY. Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials. Inflamm Bowel Dis 2016;22:933-9. [PMID: 26818417 DOI: 10.1097/MIB.0000000000000680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
411 Strik AS, Bots SJA, D’haens G, Löwenberg M. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology 2015;9:429-39. [DOI: 10.1586/17512433.2016.1133288] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
412 Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis. 2016;10:812-820. [PMID: 26818659 DOI: 10.1093/ecco-jcc/jjw032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
413 Lee DS, Bang KB, Kim JY, Jung YS, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. The prevalence and clinical characteristics of anemia in Korean patients with inflammatory bowel disease. Intest Res. 2016;14:43-49. [PMID: 26884734 DOI: 10.5217/ir.2016.14.1.43] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
414 Qiu Y, Mao R, Zhang SH, Li MY, Guo J, Chen BL, He Y, Zeng ZR, Chen MH. Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort. Medicine (Baltimore). 2015;94:e1513. [PMID: 26469893 DOI: 10.1097/md.0000000000001513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
415 Holdam AS, Bager P, Dahlerup JF. Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting. Scand J Gastroenterol 2016;51:706-11. [PMID: 26794211 DOI: 10.3109/00365521.2015.1136352] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
416 Brückner M, Lenz P, Mücke MM, Gohar F, Willeke P, Domagk D, Bettenworth D. Diagnostic imaging advances in murine models of colitis. World J Gastroenterol 2016; 22(3): 996-1007 [PMID: 26811642 DOI: 10.3748/wjg.v22.i3.996] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
417 Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol 2016; 22(3): 1078-1087 [PMID: 26811648 DOI: 10.3748/wjg.v22.i3.1078] [Cited by in CrossRef: 128] [Cited by in F6Publishing: 107] [Article Influence: 21.3] [Reference Citation Analysis]
418 Manser CN, Borovicka J, Seibold F, Vavricka SR, Lakatos PL, Fried M, Rogler G; investigators of the Swiss Inflammatory Bowel Disease Cohort Study. Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J. 2016;4:281-287. [PMID: 27087958 DOI: 10.1177/2050640615627533] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
419 Kristensen V, Klepp P, Cvancarova M, Røseth A, Skar V, Moum B. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohns Colitis. 2015;9:164-169. [PMID: 25518057 DOI: 10.1093/ecco-jcc/jju015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
420 Sood R, Ansari S, Clark T, Hamlin PJ, Ford AC. Long-term efficacy and safety of azathioprine in ulcerative colitis. J Crohns Colitis 2015;9:191-7. [PMID: 25518053 DOI: 10.1093/ecco-jcc/jju010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
421 Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Dig Liver Dis. 2016;48:360-370. [PMID: 26821929 DOI: 10.1016/j.dld.2015.12.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
422 Cars T, Wettermark B, Löfberg R, Eriksson I, Sundström J, Lördal M. Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease. J Crohns Colitis 2016;10:556-65. [PMID: 26733406 DOI: 10.1093/ecco-jcc/jjv243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
423 Hellström AE, Färkkilä M, Kolho KL. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Scand J Gastroenterol 2016;51:563-71. [PMID: 26728295 DOI: 10.3109/00365521.2015.1125524] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
424 Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482-513. [PMID: 26725569 DOI: 10.1111/apt.13491] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
425 Filipe V, Allen PB, Peyrin-biroulet L. Self-medication with steroids in inflammatory bowel disease. Digestive and Liver Disease 2016;48:23-6. [DOI: 10.1016/j.dld.2015.10.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
426 Alexakis C, Pollok RCG. Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. World J Gastrointest Surg 2015; 7(12): 360-369 [PMID: 26730281 DOI: 10.4240/wjgs.v7.i12.360] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
427 Huoponen S, Blom M. A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. PLoS One 2015;10:e0145087. [PMID: 26675292 DOI: 10.1371/journal.pone.0145087] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
428 Stallmach A, Schmidt C, Teich N. Vedolizumab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2015;10:165-75. [DOI: 10.1586/17474124.2016.1123618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
429 Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150:734-757.e1. [PMID: 26688268 DOI: 10.1053/j.gastro.2015.12.003] [Cited by in Crossref: 224] [Cited by in F6Publishing: 239] [Article Influence: 32.0] [Reference Citation Analysis]
430 Varzari A, Deyneko IV, Tudor E, Turcan S. Polymorphisms of glutathione S-transferase and methylenetetrahydrofolate reductase genes in Moldavian patients with ulcerative colitis: Genotype-phenotype correlation. Meta Gene 2016;7:76-82. [PMID: 26862484 DOI: 10.1016/j.mgene.2015.12.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
431 Andus T. Chronisch-entzündliche Darmerkrankungen: Wissenschaft heute – Standard morgen, Koloproktologie UPDATE 2015. coloproctology 2016;38:314-25. [DOI: 10.1007/s00053-015-0064-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
432 Kristensen V, Malmstrøm GH, Skar V, Røseth A, Moum B. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scandinavian Journal of Gastroenterology 2016;51:548-55. [DOI: 10.3109/00365521.2015.1117650] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
433 Volonaki E, Mutalib M, Kiparissi F, Shah N, Lindley KJ, Elawad M. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis: . European Journal of Gastroenterology & Hepatology 2015;27:1425-8. [DOI: 10.1097/meg.0000000000000470] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
434 Bohl JL, Sobba K. Indications and Options for Surgery in Ulcerative Colitis. Surgical Clinics of North America 2015;95:1211-32. [DOI: 10.1016/j.suc.2015.07.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
435 Moreau J, Mas E. Drug resistance in inflammatory bowel diseases. Curr Opin Pharmacol. 2015;25:56-61. [PMID: 26645664 DOI: 10.1016/j.coph.2015.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
436 Quetglas EG, Mujagic Z, Wigge S, Keszthelyi D, Wachten S, Masclee A, Reinisch W. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol 2015; 21(44): 12519-12543 [PMID: 26640330 DOI: 10.3748/wjg.v21.i44.12519] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
437 Naganuma M, Aoyama N, Suzuki Y, Nishino H, Kobayashi K, Hirai F, Watanabe K, Hibi T. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. J Crohns Colitis 2016;10:828-36. [PMID: 26577683 DOI: 10.1093/ecco-jcc/jjv208] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
438 Romanin DE, Llopis S, Genovés S, Martorell P, Ramón VD, Garrote GL, Rumbo M. Probiotic yeast Kluyveromyces marxianus CIDCA 8154 shows anti-inflammatory and anti-oxidative stress properties in in vivo models. Benef Microbes 2016;7:83-93. [PMID: 26565081 DOI: 10.3920/BM2015.0066] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
439 Conigliaro P, Chimenti MS, Ascolani M, Triggianese P, Novelli L, Onali S, Lolli E, Calabrese E, Petruzziello C, Pallone F. Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients. Autoimmun Rev. 2016;15:184-190. [PMID: 26554932 DOI: 10.1016/j.autrev.2015.11.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
440 Lichtenstein GR. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis. Dig Dis Sci 2016;61:358-70. [PMID: 26541989 DOI: 10.1007/s10620-015-3897-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
441 Monk JM, Lepp D, Zhang CP, Wu W, Zarepoor L, Lu JT, Pauls KP, Tsao R, Wood GA, Robinson LE, Power KA. Diets enriched with cranberry beans alter the microbiota and mitigate colitis severity and associated inflammation. J Nutr Biochem 2016;28:129-39. [PMID: 26878790 DOI: 10.1016/j.jnutbio.2015.10.014] [Cited by in Crossref: 57] [Cited by in F6Publishing: 67] [Article Influence: 8.1] [Reference Citation Analysis]
442 Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;26:CD007698. [PMID: 26497719 DOI: 10.1002/14651858.cd007698.pub3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
443 Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Théâtre E, van der Meulen-de Jong AE, Weersma RK, Wilson DC, Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW; International Inflammatory Bowel Disease Genetics Consortium. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet 2016;387:156-67. [PMID: 26490195 DOI: 10.1016/S0140-6736(15)00465-1] [Cited by in Crossref: 394] [Cited by in F6Publishing: 384] [Article Influence: 56.3] [Reference Citation Analysis]
444 Essat M, Tappenden P, Ren S, Bessey A, Archer R, Wong R, Lobo A, Hoque S. Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 2016;34:245-57. [DOI: 10.1007/s40273-015-0334-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
445 Qazi T, Shah B, El-Dib M, Farraye FA. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2016;61:589-96. [PMID: 26441281 DOI: 10.1007/s10620-015-3893-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
446 da Silva BC, Lyra AC, Mendes CM, Ribeiro CP, Lisboa SR, de Souza MT, Portela RC, Santana GO. The Demographic and Clinical Characteristics of Ulcerative Colitis in a Northeast Brazilian Population. Biomed Res Int. 2015;2015:359130. [PMID: 26509150 DOI: 10.1155/2015/359130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
447 Brown C, Gibson PR, Hart A, Kaplan GG, Kachroo S, Ding Q, Hautamaki E, Fan T, Black CM, Hu X, Beusterien K. Long-term outcomes of colectomy surgery among patients with ulcerative colitis. Springerplus 2015;4:573. [PMID: 26543708 DOI: 10.1186/s40064-015-1350-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
448 Boal Carvalho P, Dias de Castro F, Rosa B, Moreira MJ, Cotter J. Mucosal Healing in Ulcerative Colitis--When Zero is Better. J Crohns Colitis. 2016;10:20-25. [PMID: 26438714 DOI: 10.1093/ecco-jcc/jjv180] [Cited by in Crossref: 30] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
449 Fumery M, Pineton de Chambrun G, Stefanescu C, Buisson A, Bressenot A, Beaugerie L, Amiot A, Altwegg R, Savoye G, Abitbol V, Bouguen G, Simon M, Duffas J, Hébuterne X, Nancey S, Roblin X, Leteurtre E, Bommelaer G, Lefevre JH, Brunetti F, Guillon F, Bouhnik Y, Peyrin-biroulet L. Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. Clinical Gastroenterology and Hepatology 2015;13:1770-5. [DOI: 10.1016/j.cgh.2015.04.185] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 8.9] [Reference Citation Analysis]
450 McClements D, Probert C. Managing acute severe ulcerative colitis in the hosptialised setting. Frontline Gastroenterol 2015;6:241-5. [PMID: 28839817 DOI: 10.1136/flgastro-2014-100459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
451 Schmidt KJ, Müller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, Herrlinger KR, Fellermann K, Büning J. Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. J Crohns Colitis 2016;10:31-7. [PMID: 26419459 DOI: 10.1093/ecco-jcc/jjv175] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
452 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
453 Rubin DT, Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci 2015;60:3408-17. [PMID: 26386854 DOI: 10.1007/s10620-015-3868-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
454 Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182-197. [PMID: 25222660 DOI: 10.1097/mib.0000000000000202] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 16.9] [Reference Citation Analysis]
455 Devaraj B, Kaiser AM. Surgical management of ulcerative colitis in the era of biologicals. Inflamm Bowel Dis 2015;21:208-20. [PMID: 25222665 DOI: 10.1097/MIB.0000000000000178] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
456 Dumitrescu G, Amiot A, Seksik P, Baudry C, Stefanescu C, Gagniere C, Allez M, Cosnes J, Bouhnik Y. The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab. Aliment Pharmacol Ther 2015;42:1192-9. [DOI: 10.1111/apt.13393] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
457 Matsumoto S, Yoshida Y. Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study. Clin Exp Gastroenterol 2015;8:225-30. [PMID: 26347309 DOI: 10.2147/CEG.S86528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
458 Jharap B, Sandborn WJ, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015;42:1082-1092. [PMID: 26381802 DOI: 10.1111/apt.13387] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
459 Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537-545. [PMID: 26284562 DOI: 10.1038/nrgastro.2015.135] [Cited by in Crossref: 193] [Cited by in F6Publishing: 187] [Article Influence: 27.6] [Reference Citation Analysis]
460 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
461 Bennett AL, Buckton S, Lawrance I, Leong RW, Moore G, Andrews JM. Ulcerative colitis outpatient management: development and evaluation of tools to support primary care practitioners. Intern Med J 2015;45:1254-66. [PMID: 26256445 DOI: 10.1111/imj.12872] [Reference Citation Analysis]
462 van der Valk ME, Mangen MJ, Severs M, van der Have M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-camps MJ, Clemens CH, Jansen JM, van de Meeberg PC, Mahmmod N, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk C, Vermeijden JR, Siersema PD, Leenders M, Oldenburg B. Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch–Anal Anastomosis, Ileostomy and Anti-TNFα Therapy. ECCOJC 2015;9:1016-23. [DOI: 10.1093/ecco-jcc/jjv134] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
463 Bürger M, Schmidt C, Teich N, Stallmach A. Medical Therapy of Active Ulcerative Colitis. Viszeralmedizin 2015;31:236-45. [PMID: 26557831 DOI: 10.1159/000436959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
464 Jha A, Upton A, Dunlop WC, Akehurst R. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. Adv Ther 2015;32:742-56. [PMID: 26343027 DOI: 10.1007/s12325-015-0233-1] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 14.7] [Reference Citation Analysis]
465 Vassilyadi P, Harding SV, Nitschmann E, Wykes LJ. Experimental colitis and malnutrition differentially affect the metabolism of glutathione and related sulfhydryl metabolites in different tissues. Eur J Nutr 2016;55:1769-76. [DOI: 10.1007/s00394-015-0995-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
466 Pontes C, Vives R, Torres F, Panés J. Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. Inflamm Bowel Dis 2014;20:2004-12. [PMID: 25192498 DOI: 10.1097/MIB.0000000000000166] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
467 Freire P, Figueiredo P, Cardoso R, Donato MM, Ferreira M, Mendes S, Silva MR, Cipriano A, Ferreira AM, Vasconcelos H. Surveillance in ulcerative colitis: is chromoendoscopy-guided endomicroscopy always better than conventional colonoscopy? A randomized trial. Inflamm Bowel Dis. 2014;20:2038-2045. [PMID: 25185683 DOI: 10.1097/mib.0000000000000176] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
468 Jeuring SFG, Bours PHA, Zeegers MP, Ambergen TW, van den Heuvel TR, Romberg-camps MJL, van Bodegraven AA, Oostenbrug LE, Breukink SO, Stassen LPS, Hameeteman WH, Masclee AAM, Jonkers DMAE, Pierik MJ. Disease Outcome of Ulcerative Colitis in an Era of Changing Treatment Strategies: Results from the Dutch Population-Based IBDSL Cohort. ECCOJC 2015;9:837-45. [DOI: 10.1093/ecco-jcc/jjv129] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
469 Lovén Wickman U, Yngman-Uhlin P, Hjortswang H, Riegel B, Stjernman H, Hollman Frisman G. Self-Care Among Patients With Inflammatory Bowel Disease: An Interview Study. Gastroenterol Nurs 2016;39:121-8. [PMID: 26166423 DOI: 10.1097/SGA.0000000000000120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
470 Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther 2015;42:549-58. [PMID: 26140337 DOI: 10.1111/apt.13308] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
471 Narula N, Fine M, Colombel J, Marshall JK, Reinisch W. Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis. Inflammatory Bowel Diseases 2015;21:1683-94. [DOI: 10.1097/mib.0000000000000350] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 7.1] [Reference Citation Analysis]
472 Biedermann L, Fournier N, Misselwitz B, Frei P, Zeitz J, Manser CN, Pittet V, Juillerat P, von Känel R, Fried M, Vavricka SR, Rogler G; for the Swiss Inflammatory Bowel Disease Cohort Study Group. High Rates of Smoking Especially in Female Crohn’s Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation—Data from the Swiss IBD Cohort Study. ECCOJC 2015;9:819-29. [DOI: 10.1093/ecco-jcc/jjv113] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
473 Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis 2015;9:738-46. [PMID: 26094251 DOI: 10.1093/ecco-jcc/jjv101] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
474 Keohane K, Rosa M, Coulter IS, Griffin BT. Enhanced colonic delivery of ciclosporin A self-emulsifying drug delivery system encapsulated in coated minispheres. Drug Dev Ind Pharm 2016;42:245-53. [PMID: 26083078 DOI: 10.3109/03639045.2015.1044905] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
475 Annaházi A, Molnár T. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterol Res Pract 2015;2015:832395. [PMID: 26199624 DOI: 10.1155/2015/832395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
476 Lee KM, Kim YS, Seo GS, Kim TO, Yang SK; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13:193-207. [PMID: 26130993 DOI: 10.5217/ir.2015.13.3.193] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
477 Löwenberg M, Duijvis NW, Ponsioen C, van den Brink GR, Fockens P, D'Haens GR. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis. Eur J Gastroenterol Hepatol 2014;26:1240-6. [PMID: 25171024 DOI: 10.1097/MEG.0000000000000187] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
478 Jin Y, Lin Y, Lin LJ, Zheng CQ. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World J Gastroenterol 2015; 21(20): 6352-6360 [PMID: 26034371 DOI: 10.3748/wjg.v21.i20.6352] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
479 Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative Colitis Care Pathway.Gastroenterology. 2015;149:238-245. [PMID: 26025078 DOI: 10.1053/j.gastro.2015.05.036] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
480 Quetglas EG, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M, Danese S. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol 2015;71:773-99. [PMID: 26008212 DOI: 10.1007/s00228-015-1862-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
481 Orabona R, Valcamonico A, Salemme M, Manenti S, Tiberio GA, Frusca T. Fulminant ulcerative colitis in a healthy pregnant woman. World J Gastroenterol 2015; 21(19): 6060-6064 [PMID: 26019473 DOI: 10.3748/wjg.v21.i19.6060] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
482 Lutz C, Mozaffari M, Tosevski V, Caj M, Cippà P, McRae BL, Graff CL, Rogler G, Fried M, Hausmann M. Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression. Clin Exp Immunol 2015;181:343-56. [PMID: 25845418 DOI: 10.1111/cei.12635] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
483 Jamilloux Y, Sarabi M, Kérever S, Boussely N, le Sidaner A, Valgueblasse V, Carrier P, Loustaud-ratti V, Sautereau D, Fauchais A, François B, Vidal E, Collaborators. Adherence to online monitoring of patient-reported outcomes by patients with chronic inflammatory diseases: a feasibility study. Lupus 2015;24:1429-36. [DOI: 10.1177/0961203315585814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
484 Magalhães-Costa P, Matos L, Chagas C. Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event. BMJ Case Rep 2015;2015:bcr2014207928. [PMID: 25935912 DOI: 10.1136/bcr-2014-207928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
485 Wei ZZ, Li N. Application of confocal laser endomicroscopy in ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2015; 23(12): 1924-1929 [DOI: 10.11569/wcjd.v23.i12.1924] [Reference Citation Analysis]
486 Bennett AL, Munkholm P, Andrews JM. Tools for primary care management of inflammatory bowel disease: Do they exist? World J Gastroenterol 2015; 21(15): 4457-4465 [PMID: 25914455 DOI: 10.3748/wjg.v21.i15.4457] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
487 Van Assche G, Manguso F, Zibellini M, Cabriada Nuño JL, Goldis A, Tkachenko E, Varoli G, Kleczkowski D, Annese V, D'Heygere F, Balzano A; BETA study participating centers. Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study. Am J Gastroenterol 2015;110:708-15. [PMID: 25869389 DOI: 10.1038/ajg.2015.114] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
488 Pellino G, Selvaggi F. From colon-sparing techniques to pelvic ileal pouch: history and evolution of surgery for ulcerative colitis. Eur Surg 2015;47:81-90. [DOI: 10.1007/s10353-015-0309-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
489 Lindsay JO, Bergman A, Patel AS, Alesso SM, Peyrin-biroulet L. Systematic review: the financial burden of surgical complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2015;41:1066-78. [DOI: 10.1111/apt.13197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
490 Ghosh S, Daperno M. Topical Therapy in Ulcerative Colitis: Always a Bridesmaid but Never a Bride? Gastroenterology 2015;148:701-4. [DOI: 10.1053/j.gastro.2015.02.038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
491 Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Nardone OM, De Vitis I. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2014;20:1368-1374. [PMID: 24983979 DOI: 10.1097/mib.0000000000000115] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
492 Monk JM, Zhang CP, Wu W, Zarepoor L, Lu JT, Liu R, Pauls KP, Wood GA, Tsao R, Robinson LE, Power KA. White and dark kidney beans reduce colonic mucosal damage and inflammation in response to dextran sodium sulfate. J Nutr Biochem 2015;26:752-60. [PMID: 25841250 DOI: 10.1016/j.jnutbio.2015.02.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
493 American Society for Gastrointestinal Endoscopy Standards of Practice Committee. , Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 1101-21. e1-13. [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 187] [Article Influence: 24.6] [Reference Citation Analysis]
494 Corte C, Fernandopulle N, Catuneanu AM, Burger D, Cesarini M, White L, Keshav S, Travis S. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis. 2015;9:376-381. [PMID: 25770163 DOI: 10.1093/ecco-jcc/jjv047] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
495 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 220] [Article Influence: 30.1] [Reference Citation Analysis]
496 Stallmach A, Dennler U, Marschall U, Schmidt C. Patient-relevant endpoints in inflammatory bowel diseases--have changes occurred in Germany over the past twelve years? J Crohns Colitis 2015;9:390-7. [PMID: 25740812 DOI: 10.1093/ecco-jcc/jjv041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
497 Hauso Ø, Martinsen TC, Waldum H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scandinavian Journal of Gastroenterology 2015;50:933-41. [DOI: 10.3109/00365521.2015.1018937] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
498 Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2015;13:1444-9.e1. [PMID: 25724700 DOI: 10.1016/j.cgh.2015.02.019] [Cited by in Crossref: 194] [Cited by in F6Publishing: 160] [Article Influence: 27.7] [Reference Citation Analysis]
499 Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, Śliwczyński A, Diculescu MM, Kupcinskas L, Gecse KB, Gulácsi L, Lakatos PL. Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World J Gastroenterol 2015; 21(6): 1728-1737 [PMID: 25684937 DOI: 10.3748/wjg.v21.i6.1728] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
500 Lasson A, Öhman L, Stotzer PO, Isaksson S, Überbacher O, Ung KA, Strid H. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study. United European Gastroenterol J. 2015;3:72-79. [PMID: 25653861 DOI: 10.1177/2050640614560785] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
501 Brand S. Für jedes Stadium und Befallsmuster die passende Therapie wählen. MMW - Fortschritte der Medizin 2015;157:45-50. [DOI: 10.1007/s15006-015-2648-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
502 Ferrer Márquez M, Hernández Martínez Á, Reina Duarte Á, Rosado Cobián R. Current Status of the Treatment of Fulminant Colitis. Cir Esp 2015;93:276-82. [PMID: 25649534 DOI: 10.1016/j.ciresp.2014.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
503 Dige A, Støy S, Thomsen KL, Hvas CL, Agnholt J, Dahlerup JF, Møller HJ, Grønbaek H. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease. Scand J Immunol 2014;80:417-23. [PMID: 25346048 DOI: 10.1111/sji.12222] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
504 Perrotta C, Pellegrino P, Moroni E, De Palma C, Cervia D, Danelli P, Clementi E. Five-aminosalicylic Acid: an update for the reappraisal of an old drug. Gastroenterol Res Pract. 2015;2015:456895. [PMID: 25685145 DOI: 10.1155/2015/456895] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
505 Narula N, Jharap B, Colombel J. Management of Severe Ulcerative Colitis. Curr Treat Options Gastro 2015;13:59-76. [DOI: 10.1007/s11938-014-0036-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
506 Sandborn WJ, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther 2015;41:409-18. [PMID: 25588902 DOI: 10.1111/apt.13076] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
507 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21(1): 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 15.6] [Reference Citation Analysis]
508 Miyake N, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, Maeda K, Morise K, Matsushita M, Furukawa K, Funasaka K, Nakamura M, Miyahara R, Ohmiya N, Goto H. Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis. World J Gastroenterol 2015; 21(1): 254-261 [PMID: 25574099 DOI: 10.3748/wjg.v21.i1.254] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
509 Cammarota G, Ianiro G, Cianci R, Bibbò S, Gasbarrini A, Currò D. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. Pharmacol Ther 2015;149:191-212. [PMID: 25561343 DOI: 10.1016/j.pharmthera.2014.12.006] [Cited by in Crossref: 101] [Cited by in F6Publishing: 102] [Article Influence: 14.4] [Reference Citation Analysis]
510 Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis. 2014;20:1021-1028. [PMID: 24798636 DOI: 10.1097/mib.0000000000000052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis]
511 Klotz C, Barret M, Dhooge M, Oudjit A, Chaussade S, Coriat R, Abitbol V. [Management of diagnosis and treatment in ulcerative colitis]. Presse Med 2015;44:144-9. [PMID: 25534469 DOI: 10.1016/j.lpm.2014.06.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
512 Kawakami A, Tanaka M, Nishigaki M, Yoshimura N, Suzuki R, Maeda S, Kunisaki R, Yamamoto-Mitani N. A screening instrument to identify ulcerative colitis patients with the high possibility of current non-adherence to aminosalicylate medication based on the Health Belief Model: a cross-sectional study. BMC Gastroenterol 2014;14:220. [PMID: 25523298 DOI: 10.1186/s12876-014-0220-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
513 De Cassan C, Savarino E, Marson P, Tison T, Hatem G, Sturniolo GC, D’Incà R. Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. World J Gastroenterol 2014; 20(45): 17155-17162 [PMID: 25493030 DOI: 10.3748/wjg.v20.i45.17155] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
514 Gabbani T, Manetti N, Bagnoli S, Annese V. Beclomethasone dipropionate for the treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2014;3:87-96. [DOI: 10.1517/21678707.2014.968125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
515 Bringiotti R, Ierardi E, Lovero R, Losurdo G, Leo AD, Principi M. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol 2014; 5(4): 550-559 [PMID: 25400998 DOI: 10.4291/wjgp.v5.i4.550] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
516 Chen WX, Ren LH, Shi RH. Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World J Gastroenterol 2014; 20(42): 15657-15663 [PMID: 25400449 DOI: 10.3748/wjg.v20.i42.15657] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
517 Gomollón F, Rubio S, Charro M, García-López S, Muñoz F, Gisbert JP, Domènech E; En Representación de GETECCU. [Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease]. Gastroenterol Hepatol 2015;38:24-30. [PMID: 25454602 DOI: 10.1016/j.gastrohep.2014.10.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
518 Saibeni S, Kohn A, Meucci G, Papi C; Italian Group for Inflammatory Bowel Disease. How thiopurines are used for the treatment of inflammatory bowel diseases: an Italian survey. Dig Liver Dis 2015;47:170-3. [PMID: 25467827 DOI: 10.1016/j.dld.2014.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
519 Chhaya V, Saxena S, Cecil E, Chatu S, Subramanian V, Curcin V, Majeed A, Pollok RC. The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009. Aliment Pharmacol Ther. 2015;41:87-98. [PMID: 25382737 DOI: 10.1111/apt.13017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
520 Lopez A, Beaugerie L, Peyrin-Biroulet L. Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients? Expert Rev Clin Immunol 2014;10:1563-5. [PMID: 25362886 DOI: 10.1586/1744666X.2014.977261] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
521 Llaó J, Naves JE, Ruiz-cerulla A, Marín L, Mañosa M, Rodríguez-alonso L, Cabré E, Garcia-planella E, Guardiola J, Domènech E. Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. Journal of Crohn's and Colitis 2014;8:1523-8. [DOI: 10.1016/j.crohns.2014.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
522 Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J 2014;2:333-44. [PMID: 25360311 DOI: 10.1177/2050640614550672] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
523 Herrlinger KR, Stange EF, Fellermann K. Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther 2014;14:455-66. [PMID: 24450849 DOI: 10.1517/14712598.2014.880109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
524 Burri E, Beglinger C, von Felten S, Lehmann FS. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. Dig Dis Sci. 2015;60:485-491. [PMID: 25344905 DOI: 10.1007/s10620-014-3383-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
525 Jiang X, Asbach P, Hamm B, Xu K, Banzer J. MR imaging of distal ileal and colorectal chronic inflammatory bowel disease--diagnostic accuracy of 1.5 T and 3 T MRI compared to colonoscopy. Int J Colorectal Dis 2014;29:1541-50. [PMID: 25339134 DOI: 10.1007/s00384-014-2037-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
526 Moreau AC, Paul S, Del Tedesco E, Rinaudo-Gaujous M, Boukhadra N, Genin C, Peyrin-Biroulet L, Roblin X. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis. 2014;20:464-471. [PMID: 24418904 DOI: 10.1097/01.mib.0000439068.71126.00] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
527 MacFie TS, Poulsom R, Parker A, Warnes G, Boitsova T, Nijhuis A, Suraweera N, Poehlmann A, Szary J, Feakins R, Jeffery R, Harper RW, Jubb AM, Lindsay JO, Silver A. DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid. Inflamm Bowel Dis 2014;20:514-24. [PMID: 24492313 DOI: 10.1097/01.MIB.0000442012.45038.0e] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 7.5] [Reference Citation Analysis]
528 Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol 2015;13:336-8. [PMID: 25285408 DOI: 10.1016/j.cgh.2014.09.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
529 Böhm SK, Kruis W. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin Exp Gastroenterol 2014;7:369-83. [PMID: 25285021 DOI: 10.2147/CEG.S35691] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
530 Kopylov U, Battat R, Benmassaoud A, Paradis-Surprenant L, Seidman EG. Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD. Dig Dis Sci. 2015;60:478-484. [PMID: 25236422 DOI: 10.1007/s10620-014-3362-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
531 Guerra I, Bermejo F. Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol 2014;7:359-67. [PMID: 25258548 DOI: 10.2147/CEG.S45297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
532 Golik M, Kurek M, Poteralska A, Bieniek E, Marynka A, Pabich G, Liebert A, Kłopocka M, Rydzewska G. Working Group Guidelines on the nursing roles in caring for patients with Crohn's disease and ulcerative colitis in Poland. Prz Gastroenterol 2014;9:179-93. [PMID: 25276248 DOI: 10.5114/pg.2014.45098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
533 Schulze H, Esters P, Dignass A. Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. Aliment Pharmacol Ther 2014;40:991-1008. [PMID: 25200000 DOI: 10.1111/apt.12949] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
534 Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553-1563. [PMID: 25199861 DOI: 10.1016/j.mayocp.2014.07.002] [Cited by in Crossref: 127] [Cited by in F6Publishing: 134] [Article Influence: 15.9] [Reference Citation Analysis]
535 Ott C, Takses A, Obermeier F, Schnoy E, Salzberger B, Müller M. How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort. Int J Colorectal Dis 2014;29:1329-38. [PMID: 25179426 DOI: 10.1007/s00384-014-2002-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
536 Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014;63:1416-23. [PMID: 24162591 DOI: 10.1136/gutjnl-2013-305763] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 11.0] [Reference Citation Analysis]
537 Sandborn WJ, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014;8:927-35. [DOI: 10.1016/j.crohns.2014.02.021] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 11.1] [Reference Citation Analysis]
538 Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L. Addressing current treatment challenges in Crohn's disease in real life: a physician's survey. Dig Liver Dis 2014;46:1066-71. [PMID: 25169961 DOI: 10.1016/j.dld.2014.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
539 Freire P, Figueiredo P, Cardoso R, Manuel Donato M, Ferreira M, Mendes S, Silva MR, Cipriano MA, Ferreira AM, Vasconcelos H, Portela F, Sofia C. Predictive value of rectal aberrant crypt foci for intraepithelial neoplasia in ulcerative colitis – a cross-sectional study. Scandinavian Journal of Gastroenterology 2014;49:1219-29. [DOI: 10.3109/00365521.2014.951390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
540 Manguso F, Bennato R, Lombardi G, Viola A, Riccio E, Cipolletta L. Electrochemiluminescence immunoassay method underestimates cortisol suppression in ulcerative colitis patients treated with oral prednisone. World J Gastroenterol 2014; 20(31): 10895-10899 [PMID: 25152591 DOI: 10.3748/wjg.v20.i31.10895] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
541 Langhorst J, Frede A, Knott M, Pastille E, Buer J, Dobos GJ, Westendorf AM. Distinct Kinetics in the Frequency of Peripheral CD4+ T Cells in Patients with Ulcerative Colitis Experiencing a Flare during Treatment with Mesalazine or with a Herbal Preparation of Myrrh, Chamomile, and Coffee Charcoal. PLoS One. 2014;9:e104257. [PMID: 25144293 DOI: 10.1371/journal.pone.0104257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
542 Daperno M, Comberlato M, Bossa F, Biancone L, Bonanomi AG, Cassinotti A, Cosintino R, Lombardi G, Mangiarotti R, Papa A, Pica R, Rizzello F, D'Incà R, Orlando A. Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis 2014;46:969-73. [PMID: 25154049 DOI: 10.1016/j.dld.2014.07.010] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
543 Zampeli E, Gizis M, Siakavellas SI, Bamias G. Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World J Gastrointest Pathophysiol 2014; 5(3): 293-303 [PMID: 25133030 DOI: 10.4291/wjgp.v5.i3.293] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
544 Burisch J, Pedersen N, Cukovic-Cavka S, Turk N, Kaimakliotis I, Duricova D, Shonová O, Vind I, Avnstrøm S, Thorsgaard N. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis. 2014;20:36-46. [PMID: 24252978 DOI: 10.1097/01.mib.0000436277.13917.c4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
545 Nielsen OH, Coskun M, Steenholdt C, Rogler G. The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2014;9:177-89. [DOI: 10.1586/17474124.2014.945914] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
546 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
547 Maillard MH, Bortolotti M, Vader J, Mottet C, Schoepfer A, Gonvers J, Burnand B, Froehlich F, Michetti P, Pittet V. Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. Journal of Crohn's and Colitis 2014;8:825-34. [DOI: 10.1016/j.crohns.2013.12.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
548 Stacey R, Thomas L. Medical management of Crohn's disease and ulcerative colitis. Surgery (Oxford) 2014;32:418-20. [DOI: 10.1016/j.mpsur.2014.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
549 Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G. Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers. Eur J Intern Med. 2014;25:757-761. [PMID: 25086677 DOI: 10.1016/j.ejim.2014.07.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
550 Gionchetti P, Rizzello F. IBD. Sequential rescue therapy in steroid-refractory ulcerative colitis. Nat Rev Gastroenterol Hepatol 2014;11:521-3. [PMID: 25023033 DOI: 10.1038/nrgastro.2014.126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
551 Aceituno M, Zabana Y, Esteve M. [Treatment of severe ulcerative colitis flares]. Gastroenterol Hepatol 2014;37:471-9. [PMID: 25015428 DOI: 10.1016/j.gastrohep.2014.05.005] [Reference Citation Analysis]
552 Trigui A, Frikha F, Rejab H, Ben Ameur H, Triki H, Ben Amar M, Mzali R. Ileal pouch-anal anastomosis: Points of controversy. J Visc Surg. 2014;151:281-288. [PMID: 24999229 DOI: 10.1016/j.jviscsurg.2014.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
553 Shi HY, Ng SC, Tsoi KK, Wu JC, Sung JJ, Chan FK. The role of capsule endoscopy in assessing mucosal inflammation in ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:47-54. [PMID: 24966092 DOI: 10.1586/17474124.2014.934359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
554 Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;40:338-353. [PMID: 24957164 DOI: 10.1111/apt.12838] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 8.5] [Reference Citation Analysis]
555 Zarepoor L, Lu JT, Zhang C, Wu W, Lepp D, Robinson L, Wanasundara J, Cui S, Villeneuve S, Fofana B, Tsao R, Wood GA, Power KA. Dietary flaxseed intake exacerbates acute colonic mucosal injury and inflammation induced by dextran sodium sulfate. American Journal of Physiology-Gastrointestinal and Liver Physiology 2014;306:G1042-55. [DOI: 10.1152/ajpgi.00253.2013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
556 Protic M, Seibold F, Schoepfer A, Radojicic Z, Juillerat P, Bojic D, Mwinyi J, Mottet C, Jojic N, Beglinger C, Vavricka S, Rogler G, Frei P. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. J Crohns Colitis 2014;8:1427-37. [PMID: 24908178 DOI: 10.1016/j.crohns.2014.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
557 Bezzio C, Furfaro F, de Franchis R, Maconi G, Asthana AK, Ardizzone S. Ulcerative colitis: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy 2014;15:1659-70. [DOI: 10.1517/14656566.2014.925445] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
558 Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol. 2014;12:1793-1800.e1. [PMID: 24907505 DOI: 10.1016/j.cgh.2014.05.019] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
559 Zissimopoulos A, Vradelis S, Konialis M, Chadolias D, Bampali A, Constantinidis T, Efremidou E, Kouklakis G. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand J Gastroenterol. 2014;49:942-949. [PMID: 24897131 DOI: 10.3109/00365521.2014.920910] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
560 Saibeni S, Meucci G, Papi C, Manes G, Fascì-Spurio F. Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame? Expert Rev Gastroenterol Hepatol 2014;8:949-62. [PMID: 24882015 DOI: 10.1586/17474124.2014.924396] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
561 Paine ER. Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:161-168. [PMID: 24879406 DOI: 10.1093/gastro/gou028] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
562 Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol 2014;7:163-72. [PMID: 24899819 DOI: 10.2147/CEG.S45261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
563 Gecse KB, Lakatos PL. Ulcerative proctitis: an update on the pharmacotherapy and management. Expert Opinion on Pharmacotherapy 2014;15:1565-73. [DOI: 10.1517/14656566.2014.920322] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
564 Rizzo G, Pugliese D, Armuzzi A, Coco C. Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery? World J Gastroenterol 2014; 20(17): 4839-4845 [PMID: 24803795 DOI: 10.3748/wjg.v20.i17.4839] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
565 Rietdijk ST, D'Haens GR. Vedolizumab for the treatment of ulcerative colitis. Expert Rev Clin Pharmacol 2014;7:423-30. [PMID: 24802046 DOI: 10.1586/17512433.2014.911084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
566 Haag LM, Siegmund B. Exploring & exploiting our 'other self' - does the microbiota hold the key to the future therapy in Crohn's? Best Pract Res Clin Gastroenterol 2014;28:399-409. [PMID: 24913380 DOI: 10.1016/j.bpg.2014.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
567 Farkas K, Molnár T, Szepes Z. Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;8:695-702. [DOI: 10.1586/17474124.2014.909726] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
568 Triadafilopoulos G. Glucocorticoid therapy for gastrointestinal diseases. Expert Opinion on Drug Safety 2014;13:563-72. [DOI: 10.1517/14740338.2014.904852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
569 D'Haens GR, Sartor RB, Silverberg MS, Petersson J, Rutgeerts P. Future directions in inflammatory bowel disease management. J Crohns Colitis. 2014;8:726-734. [PMID: 24742736 DOI: 10.1016/j.crohns.2014.02.025] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 8.3] [Reference Citation Analysis]
570 Olivieri I, Cantini F, Castiglione F, Felice C, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Vecchi M, Armuzzi A. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev. 2014;13:822-830. [PMID: 24726868 DOI: 10.1016/j.autrev.2014.04.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
571 Cañas-Ventura A, Márquez L, Ricart E, Domènech E, Gisbert JP, García-Sanchez V, Marín-Jiménez I, Rodriguez-Moranta F, Gomollón F, Calvet X, Merino O, Garcia-Planella E, Vázquez-Romero N, Esteve M, Iborra M, Gutiérrez A, Vera M, Andreu M; Spanish GETECCU group (ENEIDA project). Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. J Crohns Colitis 2014;8:1287-93. [PMID: 24726696 DOI: 10.1016/j.crohns.2014.03.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
572 Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3516-3524 [PMID: 24707134 DOI: 10.3748/wjg.v20.i13.3516] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
573 Maconi G, Furfaro F, Sciurti R, Bezzio C, Ardizzone S, de Franchis R. Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications. World J Gastroenterol 2014; 20(13): 3507-3515 [PMID: 24707133 DOI: 10.3748/wjg.v20.i13.3507] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
574 Sozzani S, Abbracchio MP, Annese V, Danese S, De Pità O, De Sarro G, Maione S, Olivieri I, Parodi A, Sarzi-Puttini P. Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity 2014;47:287-306. [PMID: 24697663 DOI: 10.3109/08916934.2014.897333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
575 Kemp K, Sephton M. Aligning oral mesalazine treatment to health service priorities: guidance for nurses. Frontline Gastroenterol 2014;5:135-42. [PMID: 24683448 DOI: 10.1136/flgastro-2013-100357] [Reference Citation Analysis]
576 Burisch J, Pedersen N, Čuković-Čavka S, Brinar M, Kaimakliotis I, Duricova D, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Andersen V, Krabbe S, Dahlerup JF, Salupere R, Nielsen KR, Olsen J, Manninen P, Collin P, Tsianos EV, Katsanos KH, Ladefoged K, Lakatos L, Björnsson E, Ragnarsson G, Bailey Y, Odes S, Schwartz D, Martinato M, Lupinacci G, Milla M, De Padova A, D'Incà R, Beltrami M, Kupcinskas L, Kiudelis G, Turcan S, Tighineanu O, Mihu I, Magro F, Barros LF, Goldis A, Lazar D, Belousova E, Nikulina I, Hernandez V, Martinez-Ares D, Almer S, Zhulina Y, Halfvarson J, Arebi N, Sebastian S, Lakatos PL, Langholz E, Munkholm P; EpiCom-group. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014;63:588-97. [PMID: 23604131 DOI: 10.1136/gutjnl-2013-304636] [Cited by in Crossref: 243] [Cited by in F6Publishing: 221] [Article Influence: 30.4] [Reference Citation Analysis]
577 Viscido A, Capannolo A, Latella G, Caprilli R, Frieri G. Nanotechnology in the treatment of inflammatory bowel diseases. J Crohns Colitis. 2014;8:903-918. [PMID: 24686095 DOI: 10.1016/j.crohns.2014.02.024] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
578 Chebli JM, Gaburri PD, Chebli LA, da Rocha Ribeiro TC, Pinto AL, Ambrogini Júnior O, Damião AO. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit 2014;20:487-98. [PMID: 24667275 DOI: 10.12659/MSM.890331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
579 Freire P, Cardoso R, Figueiredo P, Donato MM, Ferreira M, Mendes S, Ferreira AM, Vasconcelos H, Portela F, Sofia C. NOD2 gene mutations in ulcerative colitis: useless or misunderstood? Int J Colorectal Dis. 2014;29:653-661. [PMID: 24651958 DOI: 10.1007/s00384-014-1850-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
580 Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39:1095-1103. [PMID: 24641622 DOI: 10.1111/apt.12712] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
581 Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators Inflamm 2014;2014:172821. [PMID: 24757282 DOI: 10.1155/2014/172821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
582 Pellino G, Sciaudone G, Miele E, Candilio G, De Fatico GS, Riegler G, Staiano A, Canonico S, Selvaggi F. Functional outcomes and quality of life after restorative proctocolectomy in paediatric patients: a case-control study. Gastroenterol Res Pract 2014;2014:340341. [PMID: 24744776 DOI: 10.1155/2014/340341] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
583 Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63:433-41. [PMID: 23436336 DOI: 10.1136/gutjnl-2012-304258] [Cited by in Crossref: 167] [Cited by in F6Publishing: 147] [Article Influence: 20.9] [Reference Citation Analysis]
584 Lopez A, Mounier M, Bouvier AM, Carrat F, Maynadié M, Beaugerie L, Peyrin-Biroulet L; CESAME Study Group. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1324-9. [PMID: 24582568 DOI: 10.1016/j.cgh.2014.02.026] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 8.5] [Reference Citation Analysis]
585 Zhang C, Monk JM, Lu JT, Zarepoor L, Wu W, Liu R, Pauls KP, Wood GA, Robinson L, Tsao R. Cooked navy and black bean diets improve biomarkers of colon health and reduce inflammation during colitis. Br J Nutr. 2014;111:1549-1563. [PMID: 24521520 DOI: 10.1017/s0007114513004352] [Cited by in Crossref: 57] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
586 Gionchetti P, Praticò C, Rizzello F, Calafiore A, Capozzi N, Campieri M, Calabrese C. The role of Budesonide-MMX in active ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;8:215-22. [DOI: 10.1586/17474124.2014.887437] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
587 Iborra M, Alvarez-Sotomayor D, Nos P. Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014;7:39-46. [PMID: 24523594 DOI: 10.2147/CEG.S34715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
588 Selinger CP, Kemp A, Leong RW. Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia. Expert Rev Gastroenterol Hepatol 2014;8:329-34. [PMID: 24490626 DOI: 10.1586/17474124.2014.882768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
589 Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol. 2013;29:357-362. [PMID: 23695429 DOI: 10.1097/mog.0b013e32836229fb] [Cited by in Crossref: 99] [Cited by in F6Publishing: 101] [Article Influence: 12.4] [Reference Citation Analysis]
590 Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579-594. [PMID: 24479980 DOI: 10.1111/apt.12639] [Cited by in Crossref: 130] [Cited by in F6Publishing: 116] [Article Influence: 16.3] [Reference Citation Analysis]
591 Zeitz † M, Nitschmann S. Ciclosporin oder Infliximab bei schwerer steroidrefraktärer Colitis ulcerosa: GETAID-Studie (Group d’Etudes Thérapeutiques des Affections Inflammatoires Digestives). Internist 2014;55:223-4. [DOI: 10.1007/s00108-013-3434-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
592 Guo Q, Tang ZP, Wang LJ. Progress in histopathological diagnosis of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2014; 22(2): 190-196 [DOI: 10.11569/wcjd.v22.i2.190] [Reference Citation Analysis]
593 Inokuchi T, Kato J, Hiraoka S, Suzuki H, Nakarai A, Hirakawa T, Akita M, Takahashi S, Harada K, Okada H, Yamamoto K. Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status. World J Gastroenterol 2014; 20(2): 509-517 [PMID: 24574719 DOI: 10.3748/wjg.v20.i2.509] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
594 Rizzello F, Praticò C, Calabrese C, Gionchetti P. Rescue therapy: ciclosporin or infliximab? Expert Review of Clinical Immunology 2014;9:503-5. [DOI: 10.1586/eci.13.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
595 Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther 2014;39:459-77. [PMID: 24405149 DOI: 10.1111/apt.12616] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 13.0] [Reference Citation Analysis]
596 Tan VP, Chung A, Yan BP, Gibson PR. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol. 2013;28:1095-1113. [PMID: 23662785 DOI: 10.1111/jgh.12260] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
597 Thomsen KL, Grønbæk H, Dahlerup JF, Aagaard NK, Christensen LA, Agnholt J, Frystyk J, Vilstrup H. Prednisolone but Not Infliximab Aggravates the Upregulated Hepatic Nitrogen Elimination in Patients with Active Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2014;20:7-13. [DOI: 10.1097/01.mib.0000437496.07181.4c] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
598 Ruemmele FM, Turner D. Differences in the management of pediatric and adult onset ulcerative colitis — lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis. Journal of Crohn's and Colitis 2014;8:1-4. [DOI: 10.1016/j.crohns.2013.10.006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
599 Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, Mostafa NM, Chao J, Arora V, Camez A. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283-294. [PMID: 24363029 DOI: 10.1007/s00535-013-0922-y] [Cited by in Crossref: 100] [Cited by in F6Publishing: 96] [Article Influence: 11.1] [Reference Citation Analysis]
600 Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8:197-210. [PMID: 24345070 DOI: 10.1586/17474124.2014.869476] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
601 Calvet X, Panés J, Alfaro N, Hinojosa J, Sicilia B, Gallego M, Pérez I, Lázaro y de Mercado P, Gomollón F, Aldeguera X. Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units. J Crohns Colitis. 2014;8:240-251. [PMID: 24295646 DOI: 10.1016/j.crohns.2013.10.010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
602 Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:982-1018. [DOI: 10.1016/j.crohns.2013.09.016] [Cited by in Crossref: 486] [Cited by in F6Publishing: 466] [Article Influence: 54.0] [Reference Citation Analysis]
603 Farkas K, Molnár T. Novel extended release budesonide formulation for treatment of ulcerative colitis. Expert Opin Pharmacother 2014;15:131-7. [PMID: 24219763 DOI: 10.1517/14656566.2014.860444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
604 Torres J, Danese S, Colombel JF. New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut 2013;62:1642-52. [PMID: 24104885 DOI: 10.1136/gutjnl-2012-303959] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
605 Yadav V, Gaisford S, Merchant HA, Basit AW. Colonic bacterial metabolism of corticosteroids. International Journal of Pharmaceutics 2013;457:268-74. [DOI: 10.1016/j.ijpharm.2013.09.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
606 Robinson A, Hankins M, Wiseman G, Jones M. Commentary: 5-ASA switches in IBD, adherence and flares--authors' reply. Aliment Pharmacol Ther 2013;38:1139. [PMID: 24099477 DOI: 10.1111/apt.12502] [Reference Citation Analysis]
607 Ban L, Tata LJ, Fiaschi L, Card T. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology. 2014;146:76-84. [PMID: 24126096 DOI: 10.1053/j.gastro.2013.09.061] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 6.2] [Reference Citation Analysis]
608 Pellino G, Sciaudone G, Candilio G, Camerlingo A, Marcellinaro R, Rocco F, De Fatico S, Canonico S, Selvaggi F. Complications and functional outcomes of restorative proctocolectomy for ulcerative colitis in the elderly. BMC Surg 2013;13 Suppl 2:S9. [PMID: 24267006 DOI: 10.1186/1471-2482-13-S2-S9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
609 Bryant RV, Jairath V, Curry N, Travis SP. Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk? J Crohns Colitis. 2014;8:166-171. [PMID: 24095288 DOI: 10.1016/j.crohns.2013.09.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
610 O'connor M, Bager P, Duncan J, Gaarenstroom J, Younge L, Détré P, Bredin F, Dibley L, Dignass A, Gallego Barrero M, Greveson K, Hamzawi M, Ipenburg N, Keegan D, Martinato M, Murciano Gonzalo F, Pino Donnay S, Price T, Ramirez Morros A, Verwey M, White L, van de Woude C. N-ECCO Consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis. Journal of Crohn's and Colitis 2013;7:744-64. [DOI: 10.1016/j.crohns.2013.06.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
611 Miheller P, Mandel MD, Mullner K, Lakatos PL. Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice? Expert Rev Clin Immunol 2013;9:871-82. [PMID: 24070050 DOI: 10.1586/1744666X.2013.824675] [Reference Citation Analysis]
612 Biancheri P, Powell N, Monteleone G, Lord G, MacDonald TT. The challenges of stratifying patients for trials in inflammatory bowel disease. Trends Immunol 2013;34:564-71. [PMID: 24035478 DOI: 10.1016/j.it.2013.08.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
613 Probert CS, Dignass AU, Lindgren S, Oudkerk Pool M, Marteau P. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis. 2014;8:200-207. [PMID: 24012063 DOI: 10.1016/j.crohns.2013.08.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
614 Bordeianou L, Maguire L. State-of-the-Art Surgical Approaches to the Treatment of Medically Refractory Ulcerative Colitis. J Gastrointest Surg 2013;17:2013-9. [DOI: 10.1007/s11605-013-2312-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
615 Robinson A, Hankins M, Wiseman G, Jones M. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Aliment Pharmacol Ther. 2013;38:531-538. [PMID: 23834298 DOI: 10.1111/apt.12396] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
616 Langhorst J, Varnhagen I, Schneider SB, Albrecht U, Rueffer A, Stange R, Michalsen A, Dobos GJ. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study. Aliment Pharmacol Ther 2013;38:490-500. [PMID: 23826890 DOI: 10.1111/apt.12397] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
617 Watanabe M, Nishino H, Sameshima Y, Ota A, Nakamura S, Hibi T. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study. Aliment Pharmacol Ther. 2013;38:264-273. [PMID: 23734840 DOI: 10.1111/apt.12362] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
618 Mehta SJ, Silver AR, Lindsay JO. Review article: strategies for the management of chronic unremitting ulcerative colitis. Aliment Pharmacol Ther 2013;38:77-97. [DOI: 10.1111/apt.12345] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
619 Gledhill T, Bodger K. New and emerging treatments for ulcerative colitis: a focus on vedolizumab. Biologics. 2013;7:123-130. [PMID: 23723689 DOI: 10.2147/btt.s30416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
620 Rietdijk ST, D'haens GR. Recent developments in the treatment of inflammatory bowel disease: Recent developments in IBD treatment. Journal of Digestive Diseases 2013;14:282-7. [DOI: 10.1111/1751-2980.12048] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
621 Armuzzi A, Pugliese D, Nardone OM, Guidi L. Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. Drug Des Devel Ther. 2013;7:289-296. [PMID: 23630414 DOI: 10.2147/dddt.s33197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
622 Seibold F, Fournier N, Beglinger C, Mottet C, Pittet V, Rogler G. Topical therapy is underused in patients with ulcerative colitis. J Crohns Colitis. 2014;8:56-63. [PMID: 23566922 DOI: 10.1016/j.crohns.2013.03.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
623 Kemp K, Griffiths J, Campbell S, Lovell K. An exploration of the follow-up up needs of patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:e386-e395. [PMID: 23541150 DOI: 10.1016/j.crohns.2013.03.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]
624 Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JWD, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV Jr, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145: 149-157. e2. [PMID: 23528626 DOI: 10.1053/j.gastro.2013.03.025] [Cited by in Crossref: 140] [Cited by in F6Publishing: 147] [Article Influence: 15.6] [Reference Citation Analysis]
625 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
626 Simon M. Rectocolite hémorragique: traitement médical. Colon Rectum 2013;7:11-7. [DOI: 10.1007/s11725-013-0434-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
627 Katsuno T, Saito K, Yokosuka O. Letter: should colectomy be the end-point to evaluate the effectiveness of drug therapies in severe ulcerative colitis? Authors' reply. Aliment Pharmacol Ther 2013;37:161. [PMID: 23205481 DOI: 10.1111/apt.12139] [Reference Citation Analysis]